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1. Introduction  
1.1. Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects 
multiple organ systems (musculoskeletal, dermatologic, hematologic, cardiac, pulmonary, 
renal and CNS). In SLE, the immune system is impaired, accompanied by loss of central 
and peripheral tolerance, which leads to formation of immune-complexes which are 
stimulatory and get deposited in different organs and leads to their damage (Isenberg et 
al, 2007; Manson et al, 2006; Childs et al, 2006; Marshak-Rothstein and Rifkin, 2006). 
SLE is one of the major autoimmune diseases which is often associated with high titers of 
IgG autoantibodies reactive with ubiquitously expressed intracellular autoantigens. Such 
autoantibodies and immune-complex containing autoantibodies accumulate in joints, 
kidneys, and other tissues, where they provoke inflammatory responses leading to tissue 
damage and destruction (Marshak-Rothstein, 2006). In many patients affected with SLE, 
autoantibodies are directed against relatively limited set of nucleoprotein particles (Plotz 
et al, 2003). Considerable circumstantial evidence links both onset and recurrence of 
systemic disease with various types of infections (Phillips et al, 1972; Denman et al, 
2000). The theories claimed for the lupus are as follows-  
1) At cellular level apoptosis is significantly higher and the clearance of apoptotic bodies 
is decreased. 2) The second theory is interferon signature. Gene microarray studies have 
demonstrated that 100 interferon responsive genes are activated in SLE.  
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1.2. Incidence and prevalence 
 
SLE is more predominant in females than in males and the predicted female : male ratio 
is 9:1 for the incidence of the disease. A study from Birmingham, UK, found the 
prevalence in the general population to be 27.7 in 100,000 and nine times higher in Afro-
Caribbean females. A study by NHS in USA has found the prevalence of 53.6 in 100,000. 
SLE is more common in Hispanic Americans, Asians, and African-Carribeans. On an 
average the age of onset for SLE is usually in the early 20s or 30s and the 10 year 
survival probability is 92%, which gets reduced to 88% in the patients with nephropathy 
(Manson et al, 2006; Isenberg et al, 2007). Mean age at death was found to be 44 yrs 
(varied from 18-81 yrs). Renal lupus was accounted for the largest number of deaths of 
SLE patients with less than 5 yrs of disease (Manson et al, 2006; Childs et al, 2006; 
Isenberg et al, 2007; Simard et al, 2007). Renal lupus shows immune-complex 
glomerulonephritis as a prominent feature (Anders et al, 2007a, Anders et al 2007b). 
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1.3. Pathological implications and symptoms 
Table 1: Systems affected in SLE correlated with percentage of patients. 
Affected organ system % Of 
patients 
Signs and symptoms 
Constitutional 50-100 Fatigue, fever, weight loss 
Skin 73 Butterfly rash, photosensitivity rash, mucus 
membrane lesion, Reynaud’s phenomenon 
Musculoskeletal 62-67 Arthritis, artharlgia 
Renal 16-38 Hematuria, proteinuria, nephrotic syndrome, 
cellular casts 
Hematologic 36 Anaemia, leucopoenia 
Reticuloendothelial 7-23 Lymphadenopathy, splenomegaly 
Neuropsychiatric 12-21 Psychosis, Seizures 
Gastrointestinal 18 Abdominal pain, vomiting 
Cardiac 15 Peri-, endo-, myo-carditis 
Pulmonary 2-12 Pleurisy, pulmonary hypertension 
 
(Gill et al, 2003) 
 
1.4. Causative factors for SLE 

a) Genetical  
Genes that contribute to the pathogenesis of systemic lupus are classified as follows: 1) 
Genes that cause break in tolerance for the self-antigens. 2) Genes that lead to immune 
dysregulation (loss of control of regulatory lymphocytes over the autoreactive 
lymphocytes). 3) Genes that lead to immune complex deposition (RNA and DNA 
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associated immune complexes and others) (Simard et al, 2007; Mok et al, 2003) 
(Michelle Petri, 2006). It is also suggested that multiple mutations, inherited or somatic, 
may be needed before a self-reactive clone B and T lymphocytes bypasses sequential 
tolerance check points resulting in emergence of autoimmune disease (Goodnow, 2007). 
 
b) Hormonal 
 
SLE is predominantly a postpubertal female disease however till date the hormonal 
reasons behind the disease remain complex. In men with SLE, the androgens worsen the 
disease (Simard, 2007; Mock, 2003). The incidence of lupus in women is higher as 
compared to men, female: male ratio is 9:1 (Isenberg, 2007). 
 
c) Immunological 
 
The immune system is dysregulated and increased generation of autoreactive B and T 
cells takes place alongwith the reduction in regulatory T cells. The regulatory T cells 
loses its control on the expansion of T cells. Also peripherally circulating autoantigens or 
immune-complexes which are not antigenic in healthy conditions in normal individuals 
whereas in lupus such autoantigens are recognised as danger signals which further lead to 
excessive activation of immune system. (Goodnow, 2007; Marshak-Rothstein, 2006 ; 
Simard et al, 2007; Mok et al, 2003). In immune system many tolerance checkpoints 
exist to prevent self antigens from stimulating the relentless growth of self-reactive B and 
T lymphocytes (Goodnow, 2007). These checkpoints when bypassed leads to the 
emergence of autoimmune disease. 
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d) Environmental 
 
Ultraviolet (UV), UV-A and UV-B, light has been classified as the classic environmental 
precipitant of SLE. Drugs like minocycline, and anti-TNF biologics, can lead to drug 
induced lupus erythematosus (DILE). Sulfonamide antibiotics can induce idiopathic SLE. 
Subacute cutaneous lupus erythematosus (SCLE), is associated with thiazides, calcium 
channel blockers and angiotensin-converting enzyme inhibitors. Epstein Barr viral 
infection has been strongly associated with SLE, in both children and adults in multicase 
SLE families. Amongst the other factors which are also associated with SLE are toxic 
exposures to silica and mercury (Simard et al, 2007; Mok et al, 2003). 
 
1.5. Morbidity and mortality 
Organ damage in SLE progresses over time (Gladman et al, 2000)). A cohort study 
(Rivest, 2000) found that within seven years of diagnosis, 61% of patients developed 
clinically detectable organ damage, with neuropsychiatric (20.5%), musculoskeletal 
(18.5%) and renal (15.5%) organ systems most commonly affected. Infections and 
diseases of CVS, renal, pulmonary, CNS are frequent causes of death in patients with 
SLE (Carneiro et al, 1999, Jonsson et al, 1989, Stahl-Hallengren et al, 2000, Cervera et 
al, 1999, Mok et al, 1999). Since the 1950s, five year survival rate for patients with SLE 
has increased from 50% to 91-97% (Carneiro et al, 1999; Jonsson et al, 1989; Stahl-
Hallengren et al, 2000; Mok et al, 1999, Uramoto et al 1999, Urowitz et al 1997). Higher 
mortality rates for SLE are particularly high in children. In a retrospective study of 
Brazilian children, overall mortality during 16 years of follow up was 24% (Marini et al, 
1999). Death occurred because of infection (58%) CNS disease (36%), renal disease 
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(7%). When disease onset was before 15 years, renal involvement and hypertension 
predicted mortality (Simard et al, 2007). 
 
1.6. Targets used till date for the treatment of SLE  
Targets used for treatment in clinic practice are the ones which can suppress the immune 
system, although these are not selective to eliminate the cause of end organ damage in 
SLE. Furthermore these drugs have limitations and/or adverse effects too, for e.g. 
immunomodulating drugs (cyclophosphamide, methotrexate), azathioprine, 
corticosteroids (prednisone), mycophenolate mofetil, antimalarials (chloroquine or 
hydroxychloroquine), non-steroidal anti-inflammatory drugs (Buhaescu et al, 2007; 
Davidson et al, 2006). The recent targets have been evolved to be more specific, targeting 
either the B cells (rituximab- anti CD-20 antibody), or TNF- blockade (infliximab, 
etanercept), or by competitively antagonising autoantibodies (using abetimus sodium- 
LJP 394), or blocking the cytotoxic T-lymphocyte antigen- 4 (abatacept and belatacept -
CTLA4-Ig) (Schneider et al, 2007; Waldman et al, 2006; Buhaescu et al, 2007). Recent 
experimental data have shown the trend to selectively block the receptor responsible for 
the progression of lupus or autoimmunity such as TLR9 binding to DNA-immune 
complex, or blocking Complement 5A with corresponding antagonist (Patole, 2005; 
Anders et al, 2005; Ponticelli, 2006; Schneider, 2007; Buhaescu et al, 2007). 
 
1.7. Pathogen recognition and innate immune system 
Pattern recognition receptors (PRRs) are the novel key players of immune responses in 
humans by recognizing pathogen associated molecular patterns (PAMPs). PRRs play a 
major role in host defence against viral, bacterial, and fungal pathogens by initiating both 
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innate and adaptive immune responses. PRR activation can differentially modulate 
immune responses in cases of infection and autoimmune disorders. These receptors are 
classified as Toll like receptors, nucleic acid specific-cytoplasmic receptors (RIG like 
helicases) and NOD like receptors (Lee and Kim, 2007, Anders et al, 2007a). 
 
1.7.1. Toll like receptors  
Toll-like receptor (TLR) superfamily of pattern recognition receptors is comprised of 13 
members characterized in mice (TLR1-13) and 11 in humans (TLR1-11). All TLRs 
known in mammals are type 1 integral membrane glycoproteins containing an 
extracellular domain with leucine rich repeats (LRRs) responsible for ligand recognition 
and cytoplasmic toll/IL-1R homology (TIR) domain required for initiating signalling 
(Akira et al, 2004). TLRs are generally classified into cell membrane receptors and 
endosomal receptors. Majority of TLRs are expressed by cells of immune system. Till 
date number of the exogenous and endogenous ligands of TLRs have been found out 
(Marshak-Rothstein, 2006).  
 
a) TLR1/2/6 
TLR1, TLR2 and TLR6 are expressed on cell membrane of immune and non-immune 
cells and either of them need to be heterodimerized for the recognition of the ligands 
from pathogenic microorganisms. TLR1/2 dimer can recognize triacylated lipopeptide 
such as Pam3CSK4, TLR2/6 dimer can recognise diacylated lipopeptide such as MALP-2 
(mycoplasma-derived macrophage-activating lipopeptide. TLR2, in concert with dectin-
1, can recognize zymosan (Brown et al, 2006). Upon ligand recognition, TLR2 recruits 
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both the sorting adaptor TIRAP and the signalling adaptor MyD88, and initiates the 
MyD88-dependent pathway, leading to inflammatory cytokine production (Beutler et al, 
2006). 
 
b) TLR4 
TLR4 is present on the cell membrane and is the only receptor which in association with 
CD14 and MD2 can initiate signals upon recognition of lipopolysaccharide (LPS) in 
humans and mice (Akira et al, 2006). TLR4 can activate two separate downstream 
pathways, MyD88 dependent and TRIF-dependent (Akira et al, 2006). The main role of 
MyD88-dependent pathway downstream of TLR4 is to induce the expression of 
inflammatory cytokines such as IL-6, IL-12, and TNF-alpha. The TRIF-dependent 
pathway induces the upregulation of costimulatory molecules and expression of type I 
IFNs (Kawai et al, 2005; Hobe et al, 2003a; Hoebe et al, 2003b). The MyD88-dependent 
pathway in TLR4 and TLR2 requires the recruitment of TIRAP and MyD88 via 
homophilic TIR-TIR interactions (Akira et al, 2006).  
 
c) TLR3 
TLR3 is the endosomal TLR which for the downstream signalling needs an adaptor 
molecule TRIF. TLR3 is a receptor for double stranded RNA (dsRNA), which is a viral 
PAMP, and its synthetic analogue poly (I:C). Recently it was reported that synthetic 
ssRNA such as polyinosinic acid can also stimulate the TLR3 (Marshall-Clarke et al, 
2007). The signalling pathways of TLR3 are initiated by recruitment of TRIF, which then 
activates the TRIF-dependent pathway, leading to the subsequent production of 
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inflammatory cytokines and type 1 IFNs and to the upregulation of costimulatory 
molecules. Poly (I:C) can stimulate the myeloid DCs to express type I IFNs and 
inflammatory cytokines, whereas their expression is reduced but not abolished, in cells 
from TLR3-/- mice (Alexopoulou et al, 2001). This indicates that TLR3 is a receptor for 
dsRNA but additional sensors might also exist, which have been recently discovered and 
referred as CARD helicases. A recent finding describes an important in vivo role of 
TLR3, which is to promote cross-priming for initiation of a CD8+ T cell response against 
viruses that do not directly infect DCs (Schulz et al, 2005).  
 
d) TLR 7/8/9 
TLR7/8/9 are the endosomal TLRs and they have similar downstream signalling 
pathways via adaptor MyD88. TLR7 can recognize ssRNA derived from ssRNA viruses 
such as vesicular stomatitis virus (VSV), as well as synthetic ssRNA40 and poly-U RNA 
(Alter et al, 2007; Fink et al, 2006; Marshall-Clarke et al, 2006; Heil et al, 2004, 
Savarese et al, 2006). TLR7 can also recognize synthetic small molecules of the 
imidazoquinoline family such as resiquimod, imiquimod, gardiquimod. TLR8 is active in 
humans but not in mouse (Kawai et al, 2006). TLR9 recognizes synthetic CpG 
oligonucleotides of type A, B and C and unmethylated CpG motifs in bacterial and viral 
DNA. TLR7 and TLR9 are highly expressed in pDCs, a subset of DCs, but not in cDCs. 
They induce the rapid secretion of large quantity of IFN-alpha and production of 
inflammatory cytokines, upon stimulation with the viral nucleic acids (Kawai et al, 2004; 
Liu et al, 2005). Both responses absolutely depend on the TIR adaptor MyD88 and 
subsequently on IRAK4 (Figure 1). Two signalling pathways of TLR7/9 are thought to 
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induce inflammatory cytokine expression: the MyD88-TRAF6-TAK1-MAPK/IKK-AP-
1/NF-kB pathway because TAK1-/- B cells show reduced activation of NFB and MAP 
kinases upon TLR9 stimulation (Sato et al, 2005; Takaoka et al, 2005). IRF7 
constitutively expressed in pDCs can be incorporated into a multiprotein complex 
comprising at least MyD88, IRAK4, IRAK1, TRAF6 and TRAF3 is severely impaired in 
IRAK1-/- and TRAF3-/- cells and is abolished in IRF7-/- cells, but the production of 
other inflammatory cytokines is not defective in these cells (Oganesyan et al, 2006; 
Hacker et al, 2006; Kawai et al, 2004; Honda et al, 2004; Honda et al, 2005; Uematsu et 
al, 2005). Furthermore IRF7 activation is impaired in IRAK-/- pDCs upon TLR9 
stimulation. TRAF3 associates with MyD88 and IRAK1, and synergises with them in 
activating IRF7 upon overexpression (Hacker et al, 2006; Uematsu et al, 2005). These 
data together suggest that TRAF3 and IRAK1 are responsible for IRF7 activation and 
subsequent IFN-alpha production downstream of TLR7-MyD88-IRAK4 and TLR9-
MyD88-IRAK4 (Figure 1). Recently it has been reported that IKK is required for the 
production of IFN downstream of TLR7 and TLR9 but not for other inflammatory 
cytokines. In addition it has been reported that IKK is also associated with the 
phosphorylation of IRF7 (Hoshino et al, 2006). It has been reported recently that the 
TLR9-MyD88-IRF7- dependent IFN production depends partly on the ability of pDCs 
to retain CpG-DNA in endosomes for a long time before it is translocated to the 
lysosomes for degradation. This suggests that the location and duration of ligand 
exposure to the TLRs influence the final activation response. The role of TLRs in 
mediating the pathogen recognition in case of viral infection is not much clear since even 
the mice lacking the MyD88 or TLR9 can still control replication of DNA and RNA 
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viruses and TLR independent type I IFN production in response to viral infection (Krug 
et al, 2004; Kato et al, 2005; Kato et al, 2006, Figure 1). Since the nucleic acid specific 
receptors are located in the endosomal compartments it prevents the exposure of the self 
nucleic acids to it and the generation of autoimmune reactions by self RNA and DNA 
molecules; also due to various modifications of the host RNA it is lesser potent in 
activating the DCs than unmodified RNAs (Kariko et al, 2005).  
 
 
 
 
 
Figure 1: Signaling pathways downstream of TLR7 and TLR9 in immune cells and their 
microbial ligands are shown in this figure (adopted from Akira et al, 2006). 
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1.7.2. Cytoplasmic RNA sensors or CARD helicases 
These are the PRRs which can detect the viral nucleic acids other than by endosomal 
TLRs. Retinoic acid inducible gene- I (RIG-I) and melanoma differentiation associated 
factor-5 (MDA-5) are RNA sensors, which has Dead/H box RNA helicase domain 
responsible for ligand recognition and two CARD domains essential for downstream 
signalling (Yoneyama et al, 2004; Andrejeva et al, 2004). RIG-I is essential for the 
production of interferons in response to RNA viruses including paramyxoviruses, 
influenza virus and Japanese encephalitis virus (Kato et al, 2006). MDA5 has been 
recently reported as a sensor of poly (I:C)- synthetic dsRNA and is critical for poly (I:C) 
induced type 1 IFN response, in murine embryonic fibroblasts, bone marrow derived 
DCs, bone marrow derived macrophages (Kato et al, 2006). MDA-5 is also critical for 
the antiviral response to the infection by picornaviruses, such as encephalomyocarditis 
virus (EMCV) (Kato et al, 2006). LGP2, a homolog of RIG-I/MDA5 lacking CARD 
domains, is thought to have a negative role in signalling from this helicases 
(Rothenfusser et al, 2005).  
 
1.7.3. NOD-like recptors 
Nod like receptors (NLRs) constitute a distinct family of 20 members of cytoplasmic 
PRRs in mammals (Inohara et al, Ting et al, 2006; Martinon et al, 2005). Subfamilies of 
NLRs have been grouped based on their effector functions such as NODs, NALPs, 
CIITA, IPAF, NAIPs. NODs and IPAF contains CARD effector domains, whereas 
NALPs contain pyrin (PYD) domains and NAIPs contain BIR domains (Martinon et al, 
2005). The function of NLRs is to recognise the cytoplasmic microbial PAMPs and/or 
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endogenous ligands, initiating immunological responses. 
 
1.8. Potential role of TLRs in SLE pathogenesis 
Significantly high proportion of autoantibodies which can bind to DNA or RNA or RNA 
associated proteins are associated with systemic autoimmune diseases such as SLE, 
Sjögrens syndrome, scleroderma. The mechanisms of how such epitopes, which are 
considered as harmless under normal healthy conditions turns out to be danger signals in 
autoimmune diseases remains poorly understood. Out of the numerous possibilities, one 
might be that these intracellular autoantigens become visible to immune system when 
they accumulate on cell surface during apoptotic cell death (Cascieola Rosen et al, 1994) 
and subsequent uptake of immune-complexes by activated APCs leads to loss of 
tolerance. Another possibility is that apoptosis results in cleavage of such molecules by 
granzyme B, proteases, nucleases (Rosen et al, 1999), thereby creating neoepitopes 
which can be recognised as foreign material by cells of adaptive immune system. 
Neoepitopes could also be generated by other forms of post-translational factors (Utz et 
al, 2000; Plotz et al, 2000). Till date many studies have accumulated the data in support 
of the idea that autoantigens are autoadjuvants which have the capacity to activate the 
innate immune system directly and promote self directed immune responses. Many 
adjuvants have been confirmed to stimulate the innate immune system through PRRs, and 
it is becoming increasingly evident that many of the same PRRs are also involved in 
response to injury, the clearance of apoptotic cell debris, and the repair of damaged 
tissues. 
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Endogenous danger signals in autoimmunity 
The major cellular coordinators of autoimmunity have recently been studied in great 
detail and these are the ligands acting through TLR7 and TLR9 (Figure 2). The drugs 
which inhibit the endosomal acidification and/or maturation are also able to inhibit the 
signalling cascades initiated by activation of TLR7 and 9. These two receptors are 
constitutively expressed by B cells, plasmacytoid dendritic cells, and macrophages, 
which are playing a major role in the pathogenesis in SLE and other systemic diseases 
through the production of autoantibodies, IFN-alpha, and other proinflammatory 
cytokines (Figure 2). It has been reported that DNA immune complexes are recognised 
by TLR9 and RNA immune complexes by TLR7, respectively (Marshak-Rothstein and 
Rifkin, 2007, Anders et al, 2005). 
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Figure 2: Cycle of responses by immune cells to autoantigens released by cell death- a. 
virus infection, b. IFN- upregulates TLR7 in B cells, and produces other actions, c. 
Autoreactive B cells with TLR7, d. B cell receptors deliver RNA autoantigen to TLR7, e. 
B cells produce autoantibody, f. immune complexes bind to Fc receptors. g. autoantigen 
internalization (figure adopted from Marshak-Rothstein, 2006). 
 
 
Lerner et al had discovered that the RNP and Sm antigens recognized by lupus 
erythematosus antibodies are located on discrete particles containing single small nuclear 
RNA’s complexed with proteins, the antigens Ro and La are also on ribonucleoproteins 
(Lerner et al, 1981). The small RNA’s in ribonucleoproteins with Ro are discrete, like 
those associated with RNP and Sm; in contrast ribonucleoproteins with La contain a 
striking highly banded spectrum of small RNA’s from uninfected cells as well as virus 
associated RNA from adenovirus-infected cells (Lerner et al, 1981). U1 snRNP (small 
nuclear ribonuclear protein) which is a potent autoantigen in systemic autoimmune 
disease such as SLE (van Venrooij et al, 1995, Figure 3) and is now found to be the 
TLR7 ligand from the laboratory of Anne Krug (Savarese, 2006). Stark et al for the first 
time described the three dimensional structure of human U1 SnRNP by single particle 
electron microscopy in 2001 (Stark et al, 2001). 
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Figure 3. The RNA and protein components of U1snRNP: a. The three proteins specific 
to U1snRNP, b. Seven Sm proteins common to all snRNPs. The Sm proteins bind to the 
Sm-site RNA to generate Sm core RNP. c. Numbers indicate the relative molecular 
masses, d. The secondary structure of RNA and the sites at which proteins U1-70K and 
U1-A bind to the RNA. The Sm site is yellow and the four way junction of four double 
helical strands is grey (Adopted from Stark et al, 2001). 
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DNA containing immune-complexes are the endogenous ligands of TLR9. Synthetically 
prepared oligodeoxynucleotides using following sequences on phosphorothioate (stable) 
or phosphodiester backbone were reported to be TLR9 stimulatory or inhibitory 
(Marshak-Rothstein, 2006, Patole et al, 2005, Anders et al, 2005). 
 
Table 2: Sequences found to be TLR9 stimulatory and inhibitory in vitro. 
 
Type of ODN Name Sequence 
ODN1585 (type A. 
mouse) 
5’- ggGGTCAACGTTGAgggggg -3’ (20 mer) 
1826 (type B. mouse) 5’-tccatgacgttcctgacgtt-3’ (20 mer) 
ODN2216 (type A. 
Human 
5’-ggGGGACGA:TCGTCgggggg-3’ (20 mer) 
Stimulatory 
2006 (type B. Human) 5’-tcgtcgttttgtcgttttgtcgtt-3’ (24 mer) 
2088 (mouse) 5’-tcctggcggggaagt-3’   Inhibitory 
ODN TTAGGG 
(Human) 
5’-tttagggttagggttagggttaggg-3’  
 
 
1.8.2. Cross talk of TLR7, TLR9 cross talk with B cell receptor 
A functional link between TLR9 expression and B cell activation was first shown in 
studies involving B cell receptor transgenic murine cells. The AM14 transgenic cell line 
express receptor specificity commonly found in IgG autoantibody repertoire of FAS 
deficient MRL autoimmune prone mice (Schlomchik et al, 2003). These rheumatoid 
factor antibodies recognise IgG2a a/j which in original host is autologus IgG2a, and B cells 
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expressing this receptor escape tolerance inducing mechanisms that eliminate more avid 
self-reactive cells. DNA associated IC induces a stimulatory and proliferative response in 
AM14 cells and it is dependent on expression of both AM14 BCR and TLR9 (Leadbetter 
et al, 2002; Busconi et al, 2007). IgG2a monoclonal antibodies reactive with RNA or 
RNA associated protein are also stimulatory immune-complex (IC) for primary B cells 
and these responses are enhanced by type 1 IFN (Lau et al, 2005). Although the 
BCR/TCR paradigm was originally identified by IC activation of IgG2a reactive B cells, 
additional in vitro studies indicate that TLR engagement is involved in activation of B 
cells that bind DNA or RNA or other autoantigens and therefore play an important role in 
early stages of autoantibodies production (Figure 4). 
             
 
Figure 4: RNA and DNA specific B cells which are able to internalize the RNA or DNA 
either endogenous or exogenous and later able to bind to endosomal TLR7 or 9 
respectively (adopted from Marshak-Rothstein, 2006). 
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1.8.3. Contribution of FcR to TLR signals 
DNA and RNA containing ICs can bind to low affinity FcRs on various APCs which 
can internalize the IC and such DNA and RNA upon reaching endosomes can activate 
TLRs (Table 3, Figure 5). In recent studies carried out by using sera of SLE patients or 
other systemic autoimmune disorders, such sera can induce pDCs to produce high 
amounts of type 1 IFN, IFN- (Figure 5; Vallin et al, 1999; Ronnblom et al, 2001). BL6 
mice lacking the inhibitory FcRIIB receptor were found to produce IgG autoantibodies 
and develop glomerulonephritis (Bolland et al, 2002, Figure 5). Similar results were 
reported by mixing IgG antibodies purified from patient sera with either apoptotic or 
necrotic cell debris, as by mixing same antibodies with CpG-DNA or Sm-RNP (Vollmer 
et al, 2005; Lovgren et al, 2004; Magnusson et al, 2004; Lovgren et al 2006; Barrat et al, 
2005). Blocking antibodies to FcRIIa could inhibit IFN production. Further reports 
using TLR deficient murine PDCs as well as inhibitory ODNs and inhibitors of 
endosome acidification have linked these responses to TLR7 and TLR9 (Vollmer et al, 
2005; Barrat et al, 2005; Bave et al, 2003; Savarese et al, 2006).  
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Table 3: Different types of cells expressing FcRs and TLRs  
 
Cells expressing FcRs TLR7/8 TLR9 
pDCs (Human and murine)  + + 
CD8+ cDCs (Murine)   + 
CD8- cDCs (murine)  + + 
Skin derived mast cells  + + 
Langerhans cells   + 
Monocytes DC (human)  +  
Myeloid DCs (human)  +  
Activated neutrophils (human)  + + 
Platelets (murine, human)   + 
 
   (Marshak-Rothstein, Rifkin, 2006) 
 
             
 
Figure 5: FcR mediated internalization of immune-complexes in plasmacytoid dendritic 
cells followed by binding to endosomal TLR7 or 9 (adopted from Marshak-Rothstein,  
2006). 
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1.8.4. Systemic lupus and role of endosomal TLRs in induction of IFN 
It is well known that IFN is an inducer of clinical features of SLE (Preble et al, 1982). 
IFN family has 13 subtypes each of them have diverse functions associated with 
immune responses to viral infections (Theofilopoulos, 2005). The causal relationship of 
IFN and SLE become evident from the observation that repeated administration of 
recombinant IFN to patients with various malignancies or chronic viral infections, could 
lead to production of antinuclear antibodies (ANA), and occasionally development of 
clinical symptoms associated with SLE or other autoimmune diseases (Ronnblom et al, 
1990, Gota et al, 2003). Recent studies which examined gene expressions have identified 
IFN signature in most patients with active SLE. IFN can contribute significantly to 
disease pathogenesis through various mechanisms, including direct and indirect effects 
on APCs, T cells, B cells (Banchereau et al, 2004). Another study showed that NZB mice 
lacking type 1 IFN receptor have reduced titers of DNA antibodies and less severe renal 
disease (Lian et al, 2004; Santiago-Raber et al, 2003). 
 
A. Novel findings linking IFN signalling to genetic predisposition in systemic lupus 
Several genetic factors contribute for development of SLE. Single nucleotide 
polymorphisms are associated with type 1 IFN signalling pathway. IFN-regulatory factor-
5 (IRF-5) is constitutively expressed by B cells and PDCs and has crucial role in TLR 
induced transcription of proinflammatory cytokines (Takaoka et al, 2005). In human 
cells, IRF5 regulates expression of type 1 IFNs downstream of TLR7 but not TLR3 
(Schoenemeyer et al, 2005).  
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B. IFN and plasmacytoid dendritic cells 
It is known that majority of the amounts of IFN is produced by PDCs which were 
originally known as IFN producing cells. It was reported that the immune complexes 
(ICs) isolated from lupus patients sera could be potent stimulus for IFN production, 
especially by PDCs, that have been previously exposed to type 1 IFNs or 
granulocyte/macrophage colony stimulating factor. Similar to other APCs, PDCs express 
receptors for Fc pattern of IgG (FcRs) which can bind and internalize IgG containing 
immune complexes and function as activating receptors (Amigorena et al, 1998). 
Immune complexes from patients with SLE cannot stimulate PDCs that have been 
protected with blocking antibodies directed against FcRIIa (or CD32). In summary 
certain immune complexes have IFN inducing activity and is dependent on FcRIIa 
receptors.  
 
1.8.5. Pathogenic role of immune-complexes via TLR7 and TLR9 
Many of the common autoantigens released by dead and dying cells becomes available to 
immune system as a result of excessive cell damage or injury or inappropriate clearance 
of apoptotic cell debris (Rifkin et al, 2005). Self reactive or autoreactive B cells can 
produce the autoantibodies which constitutes 5- 20 % of naïve B cell repertoire in most 
individuals (Wardemann et al 2003). Defects in early B cell tolerance might lead to an 
even greater percentage of self-reactive B cells in patients who are prone to development 
of autoimmune disease (Yurasov et al 2005). Several mechanisms that may or may not be 
linking to each other probably accounts for activation and differentiation of these cells 
which are normally quiescent.  
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It is reported that viral and bacterial infections are frequently associated with the onset of 
systemic autoimmune disease and subsequent clinical flares (Chen et al, 2005; 
Banchereau et al, 2006), these infections might play a pivotal role in loss of tolerance and 
production of autoantibodies. It has been reported (Rönnblom et al, 2001) that 
autoantigens upon presentation by APCs can stimulate potentially autoreactive T cells 
which in turn can potentiate the activation, clonal expansion and differentiation of 
autoreactive B cells. Under appropriate conditions these B cells undergo somatic 
hypermutation of their BCR and switch to expression of pathogenic immunoglobulin 
classes. The high affinity autoreactive B cells clones are selected by autoantigens that 
become increasingly available during the course of infection, owing partly to increased 
rate of cell death, caused by inflammatory cells and cytotoxic effector cells. B cell 
differentiation might also be driven by recognition of virus infected B cells by T cells 
(Hunziker et al, 2003). Excessive amounts of cell debris and autoantibodies then form 
immune complexes which can activate PDCs and also establish a feedback loop which 
further aggravates the disease process. 
 
1.8.6. Triggers of autoantibodies generation 
Certain autoantigens can possibly play a proactive role in loss of tolerance mediated 
through PRRs. BCR mediated endocytosis, is a route available not only to 
microorganisms but also to endogenous autoantigens that are recognized by autoreactive 
BCR. Therefore self-antigens when in excessive quantities can effectively engage both 
the BCR and TLR7 or 9 and might stimulate autoreactive B cells (Table 4). Similarly 
aberrant expression and regulation of such TLRs might render B cells hyperresponsive to 
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such endogenous ligands and therefore predispose the individual to development of 
systemic autoimmune disease (Marshak-Rothstein, 2006). Several studies have shown 
that the bacterial or viral DNA or synthetic DNA rich in hypomethylated CpG motifs can 
produce significant adjuvant activity (Krieg et al, 1995; Messina et al, 1991; Sun et al, 
1997). 
By contrast purified mammalian genomic DNA has remarkably poor adjuvant activity 
which probably is due to lack of hypomethylated CpG motifs and presence of sequences 
that inhibit effective activation of TLR9 by agonist motifs (Stacey et al, 2003; Gursel et 
al, 2003, Table 2). Hence the reasons why DNA/RNA containing immune complexes in 
lupus patients sera activate PDCs, can be possibly due to FcR mediated uptake of ICs 
and delivery to intracellular compartment in PDCs and DNA/RNA binding B cells 
(Marshak-Rothstein, 2006, Rev, Yasuda et al, 2007) which might be more prevalent in 
patients with SLE. 
Particular features of mammalian RNA subtypes are also likely to confer adjuvant 
activity. Agonists for TLR7 include ssRNA that is rich in uridine or combination of 
uridine and guanosine (Diebold et al, 2006; Heil et al, 2004). Many of the SnRNPs that 
are frequently targeted by autoantibodies consist of proteins that are bound to small UG 
rich RNAs. The adjuvant activity of RNA probably gets lost upon the post translational 
modification, which renders mammalian RNA harmless or inactive to TLR7. Based on 
reduced levels of modification such as oxidation might increase the adjuvant properties of 
mammalian RNA (Busconi et al, 2006) and UV light can also cause oxidative damage to 
RNA and DNA (Emerit et al, 1981) and can generate covalent RNA-protein complexes 
(Andrade et al, 2005), and can induce apoptotic or necrotic cell death (Carrichio et al, 
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2003), all such factors can promote release of potent TLR7 and 9 ligands. 
To understand the role of exogenous bacterial or viral infections in an established lupus 
nephritis, synthetic mimic of bacterial DNA (Tlr9 ligand) and viral dsRNA (Tlr3 ligand) 
was injected in 16 weeks old lpr mice (Anders et al, 2004, Patole et al, 2005), the results 
showed that both the ligands based upon their binding affinity to the respective Tlrs could 
induce different immunological responses systemically as well as at the site of kidney. 
Injections with CpG DNA led to increase in levels of serum autoantibodies to DNA, and 
aggravated the renal injury in lpr mice (Anders et al, 2004). This proactive role of TLR9 
in aggravation of lupus nephritis was confirmed later in the studies conducted in our lab, 
using a TLR9 inhibitory oligo G-rich DNA 2114. This ODN was injected in lupus mice 
for 13 weeks which led to reduction in the levels of serum dsDNA-specific IgG2a as well 
as the renal immune complex deposits (Patole et al, 2005). Viral dsRNA mimic 
poly(I:C), upon injection in lpr mice increased serum IL-12p70, IL-6, and IFN-alpha 
levels, although serum DNA autoantibody levels were unaltered (Patole et al, 2005). 
However the role of Tlr7 activation by an exogenous ligand which either mimics viral 
ssRNA or small molecule which binds Tlr7, was unexplored in experimental systemic 
lupus in the literature. 
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Table 4: Microbial and endogenous ligands of endosomal toll like receptors and their 
disease association (Marshak-Rothstein,  2006). 
 
TLR Microbial ligand Endogenous ligand Disease 
association 
  Autoantigen Natural source 
of autoantigen 
 
TLR7 
and 
TLR8 
Single stranded RNA 
(viruses) 
Single stranded 
RNA 
ssRNA from 
dead or dying 
cells, SnRNPs 
SLE, 
scleroderma, 
Sjögrens 
syndrome 
TLR9 DNA DNA DNA from dead 
or dying cells 
SLE 
TLR3 Double stranded RNA 
(viruses) 
Double stranded 
RNA 
Necrotic cells Arthritis 
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1.8. Experimental mouse model of SLE used in this thesis 
 
The MRL/MpJ mice are large and docile mice with albino appearance and they are the 
parent and control strain for MRL/MpJ-Faslpr. Despite carrying the normal Fas gene, 
MRL/MpJ mice also exhibit autoimmune disorders, but symptoms are manifested much 
later in life compared to those the MRL/MpJ-Faslpr mice. Starting at about three months 
of age, levels of circulating immune complexes rise greatly in the MRL-Faslpr mouse but 
not in the wildtype control, MRL/MpJ. Also beginning at 3 months Faslpr mice exhibit 
very severe poliferative glomerulonephritis, whereas in the MRL/MpJ controls usually 
only mild glomerular lesions are detected. MRL/MpJ inbred female typically die at 73 
weeks of age and males die at 93 weeks. This compares to a lifespan of 17 weeks in the 
female and 22 weeks for males in the mouse homozygous for Faslpr. See MRL/MpJ-
Faslpr for additional information. As a strain developed as the control for MRL/MpJ-
Faslpr, MRL/MpJ mice are useful in the study of their comparable defects and diseases. 
The MRL/MpJ lymphoproliferation wildtype strain was generated by Jackson laboratory 
from a series of crosses with strains C57BL/6J (0.3%), C3H/HeDi (12.1%), AKR/J 
(12.6%) and LG/J (75%) and then followed by inbeeding. During development of this 
strain by Jackson Laboratory, at F12, the spontaneous mutation Faslpr was found. 
MRL/MpJ-Faslpr and the MRL/MpJ control are kept congenic with each other by 
backcrosses to the MRL/MpJ wildtype every 5-10 inbred generations. (Ref. 
http://jaxmice.jax.org/strain/000486.html) 
For convenience, MRL/MpJ-Faslpr will be termed as MRLlpr/lpr and MRL/MpJ mice 
will be termed as MRL/WT in this thesis. 
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Diagrmatic representation of Life span of MRLlpr/lpr mice 
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2. Hypothesis  
Here we gradually designed 3 hypotheses one after the other based on the results of the 
previous one for analyzing the role of Tlr7. These hypotheses were as follows- 
 
1. The recognition of exogenously exposed synthetic mimic of viral ssRNA or small 
molecule via Tlr7 may represent an important mechanism of virus-induced 
autoimmunity, e.g. in lupus. Hence it was hypothesised to characterize the expression of 
Tlr7 in experimental lupus and to study the effects of Tlr7 ligation on lupus disease 
activity as a model for intercurrent viral infection in SLE.  
 
2. In view of the reported in vitro studies it was hypothesized, whether transient exposure 
to Tlr7 ligand, imiquimod, would trigger lupus nephritis in vivo or not. Hence we planned 
to expose young lupus-prone MRLlpr/lpr mice or MRL wild-type mice to these 
compounds, so that we can also address the role of the lpr mutation for Tlr7 mediated 
effects if any on autoimmune tissue injury in MRL mice.  
 
3. According to the recent published studies, Tlr7- or Tlr9-deficiency in lupus mice have 
opposing effects on experimental lupus it became necessary to dissect therapeutic 
blockade of these Tlrs by specific antagonists. Such antagonists were identified by Barrat, 
et al. who characterized the inhibitory effects of synthetic oligodeoxynucleotides with 
immunoregulatory sequences (IRS) on Tlr7 signaling in vitro (Barrat et al, 2005). Based 
on the present evidence of a proinflammatory role of Tlr7 for lupus, it was hypothesized 
that antagonism of Tlr7 would have beneficial effects on experimental lupus. 
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3. Materials and methods   
 
3.1. Materials and methods Part 1  
 
3.1.1. Animals and Experimental Protocol 
 
Ten week old female MRLlpr/lpr mice were obtained from Harlan Winkelmann 
(Borchen, Germany) and kept in filter top cages under a 12 hour light and dark cycle. 
Water and standard chow (Sniff, Soest, Germany) were available ad libitum. All 
experimental procedures were approved by the local government authorities. At the age 
of 16 week, female MRLlpr/lpr mice were distributed into three groups that received 
intraperitoneal injections every alternate day as follows: I. 25 g of imiquimod, a 
compound of the imidazoquinoline family and Tlr7 agonist (Sequoia Research Products 
Ltd, Oxford, UK) in 100 l 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, Steinheim, 
Germany), II. 100 l 10% dimethyl sulfoxide (Merck, Darmstadt Germany), III. 100 l 
normal saline. All mice were sacrificed by cervical dislocation at the end of week 18 of 
age. To assess the renal distribution of ssRNA 3'-rhodamine-labeled ssRNA40, known to 
ligate mTlr7 (Heil et al, 2004), was injected intravenously into MRLlpr/lpr mice at the 
age 16 weeks. Renal tissue was collected 2 hours later and subjected to further analysis as 
described below. For the identification of 3'-rhodamine-labeled renal cells costaining was 
performed using rat anti-F4/80 (Serotec, Oxford, UK, 1:50). In order to assess renal Tlr7 
mRNA expression, kidneys were harvested from each group of treated mice at the end of 
18 wks of age and also from 5 and 20 week old female MRLlpr/lpr mice. 
 
3.1.2. Evaluation of autoantibodies and glomerulonephritis 
 
Blood and urine samples were collected from each animal at the end of the study period 
  - 43 - 
from each group of mice. Blood samples were collected under anesthesia by retroorbital 
puncture using capillaries and collected in 1.5 ml micro centrifuge tubes. Serum was 
collected after a settle time of 15 min at room temperature followed by centrifugation of 
blood at 10000 rpm for 5 min. Proteinuria and creatinine were determined using an 
automatic autoanalyzer (Integra 800, Roche Diagnostics, Germany).  
 
A) Analysis of serum autoantibodies 
 Serum dsDNA autoantibodies were determined by using commercial ELISA kits (Bethyl 
Labs, Montgomery, TX, USA) using the following antibodies: anti-mouse IgG1 and 
IgG2a following the manufacturer’s protocol with some modifications as follows:  
1. First calculate the number of sample wells required. Coat the sample wells in 
NUNC maxisorp 96 well flat bottom ELISA plate with 50 µg/ml (dilute in PBS) of 
the aqueous solution of 100 µl of Poly-L-Lysine (Trevigen, Gaithersburg, MD, 
USA) for 1 hour at room temperature.  
2. Wash once with washing buffer, tap dry on blotting paper and coat the sample 
wells only with 1 µg/ml of dsDNA, which can be diluted in SSC buffer (1X), pH 7 
for making the required dilution. 
3. For standard wells, capture the wells with the capture antibody in coating buffer as 
described in the protocol. 
4. Incubate the plate overnight at 4°C.  
5. Next day wash the plate with the wash buffer 3 times and then block it with 
blocking solution and follow the protocol as provided by the bethyl labs from this 
blocking step onwards. 
6. Add the standard and samples in respective wells in required dilution and allow to 
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7. Wash the plate 3 times and then add secondary antibody at given dilution as per the 
protocol and incubate it for 1 hour at room temperature. 
8. Wash the plate again as before and add TMB substrate (1:1 mixture of substrate A 
and B) in each well and incubate in dark for 5-20 minutes. 
9. Stop the reaction with 1 M H2SO4 and measure the absorbance at 450 nm. 
 
B) Morphological and histological processing 
From all mice, the tissues isolated from kidneys or spleens and placed in plastic 
histocassettes and immediately fixed in 10% buffered formalin (formaldehyde in PBS) 
for overnight and next day processed, with automatic tissue-processor (Thermo-
Shandon), which processes tissues in following manner- 70% Ethanol (for 5 hours), 96 % 
ethanol (2 hrs), 100 % ethanol 3.5 hrs, Xylene (2.5 hrs), paraffin (4 hrs). Then the 
histocassettes are taken out and the paraffin blocks are prepared with hot liquid paraffin 
using a machine (Microm- EC 350). The prepared blocks are allowed to cool down and 
later separated from the steel holders. These blocks are later used for making fine 
sections for different stainings (PAS or immunohisto). The fine sections (5µm) are 
prepared using the microtome (Microm- HM340E) and mounted gently on a glass frosted 
slide. Such slides are later allowed to dry for 2 hours in an oven at 50°C temperature. 
Deparaffinisation followed by dehydration was carried out by incubating the sections in 
xylene, 100% absolute ethanol, 95%, 80% and 50% ethanol followed by rinsing with 
PBS (2 changes, 3 minutes each). 5 μm sections for silver and periodic acid-Schiff stains 
were prepared following routine protocols for histopathology. From each mouse tissue 
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collected as mentioned above, 2 µM thick paraffin-embedded sections were cut and 
processed for immunohistochemical staining performed on paraffin-embedded sections. 
 
C) Immunostaining  
Immunostaining was either performed on paraffin-embedded or frozen sections as 
follows: using the following primary antibodies: anti-mouse Tlr7 (1:50, IMG581, 
Imgenex, San Diego, CA), anti-mouse ER-HR3 (1:50, monocytes/macrophages, DPC 
Biermann, Bad Nauheim, Germany), anti-mouse CD11c (1:50, clone HL3, BD), anti-
mouse CD3 (1:100, clone 500A2, BD), anti-mouse smooth muscle actin (1:100, 
myofibroblasts, clone 1A4, Dako, Carpinteria, CA), anti-mouse CCL5 (1:50, clone VL1, 
Peprotech, Rocky Hill, NJ), anti-mouse Ccl2/MCP-1 (1:50, polyclonal, Santa Cruz 
Biotechnology), anti-mouse Mac-2 (1:50, monocytes/macrophages, BD Pharmingen, 
Hamburg, Germany), anti mouse B220 (1:400, early Pro-B to mature B cells, clone RA3-
6B2, BD), anti-mouse Ki-67 (1:100, cell proliferation, Dianova, Hamburg, Germany); 
anti-mouse IgG1 (1:100, M32015, Caltag Laboratories, Burlingame, CA, USA), anti-
mouse IgG2a (1:100, M32215, Caltag), anti-mouse C3 (1:20, GAM/C3c/FITC, Nordic 
Immunological Laboratories, Tilburg, Netherlands). Negative controls included 
incubation with a respective isotype antibody. For quantitative analysis glomerular cells 
were counted in 10 cortical glomeruli per section. Semiquantitative scoring of glomerular 
IgG and C3c deposits from 0-3 plus was performed on 15 cortical glomerular sections. 
Semiquantitative scoring of glomerular IgG deposits from 0 to 3 was performed on 15 
cortical glomerular sections using a semiquantitative index as follows: 0 = no signal, 1 = 
low signal, 2 = moderate signal, and 3 = strong signal intensity. Peribronchial and 
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pulmonary inflammation was arbitrarily graded from 0 (no inflammation) to 3 (severe 
inflammation). 
 
3.1.3. Isolation of primary cells 
 
A. Isolation and preparation of murine bone marrow derived dendritic cells (BMDCs) 
Tibia and femur bones from the fore and hind limbs of MRL-lpr/lpr mice were isolated 
after sacrificing 4-5 mice, using all sterilized materials and sterile conditions for the 
isolation in an aseptic hood with HEPA filters. Bones were freed from the adhering 
tissues and both the ends of each bone were punctured with the 24 gauge needle and then 
the RPMI media was flushed (using sterile surgical syringe with needle) through the 
bones to isolate bone marrow in a sterile Petri plate containing the 2-3 ml of ice-cold 
media (RPMI+ 10 %FCS + 1 % PS) on ice. Then it was homogenously resuspended 
using 1 ml pipette. This cell suspension was taken in a 15 ml Falcon tube using 1 ml 
pipette and centrifuged at 1600 rpm at 4°C for 6 min. and washed with 1x PBS (cell 
culture grade) for 2 times. Then it was passed through the 40 µm sterile filters to obtain 
single cell suspension and centrifuged as before. The supernatant was decanted and the 
pellet was resuspended in 4 ml of sterile 0.3M NH4Cl and kept at room temperature for 5 
min. Then it was centrifuged as above and supernatant was decanted and pellet was 
resuspended in ice cold (cell culture use) PBS and washed 2 times with PBS as before. 
The pellet was resuspended in RPMI media (2-4 ml) and the no. of cells were counted 
using Neubar’s chamber under the microscope after suitable dilution. Adequate no. of 
cells (5 million) in 12 well plates (NUNC cell culture plates), each well containing 1.5 ml 
of complete RPMI media containing 100 ng/ml recombinant murine Flt3 ligand 
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(Immunotools, Friesoyth, Germany). The plates were incubated at 37°C for 8 days to 
obtain a lineage of mixture of plasmacytoid dendritic cells and conventional dendritic 
cells (pDC and cDC). After 4 days of incubation 1 ml of fresh media (with 100 ng/ml 
Flt3 ligand) was added in each well. After 8 days of the incubation, 2 ml of fresh media 
was replaced for the old media by careful removal only from the top of each well. Then 
the cells were stimulated with ligands or media. The plates were again incubated for 24 
hrs at 37°C. After incubation the supernatants were carefully isolated in microcentrifuge 
tubes. The cells from each well were lysed using the required amount of RLT buffer 
containing -mercaptoethanol (350 µl per well) and collected in DEPC treated sterile 
microcentrifuge tubes and stored immediately at –80°C, which were used for RNA 
isolation. The supernatants were separated from the residual amount of cells by 
centrifuging it at 6000 rpm for 10 min. And immediately stored them at –20°C. These 
supernatants were analyzed for the various cytokines, and chemokines by ELISA. 
 
B. Isolation and preparation of murine spleen monocytes 
Spleen was isolated from the MRLlpr/lpr or MRL/WT mice after sacrificing it, using all 
sterilized materials and sterile conditions for the isolation in an aseptic hood with HEPA 
filters. Spleen was collected in a sterile Petri plate containing 2-3 ml of ice-cold media 
(RPMI+ 10 %FCS + 1 % PS) on ice. Then it was mashed using forceps in the petriplate 
itself and broken into fine pieces of tissues. Then the cell suspension was passed through 
70 µm plastic filter (BD biosciences) using the 1 ml pipette and collected in another 
sterile plate. This single cell suspension was later collected in a 15 ml Falcon tube with 
pipette and centrifuged at 1600 rpm at 4°C for 6 min. The supernatant was decanted and 
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the pellet was resuspended in 4 ml of sterile 0.3M NH4Cl and kept at room temperature 5 
min. Then it was centrifuged at 1600 rpm at 4°C for 6 min. Supernatant was decanted and 
pellet was resuspended in ice cold (cell culture use) PBS and centrifuged at 1600 rpm at 
4°C for 6 min. The pellet was resuspended in RPMI media (2-4 ml) and the no. of cells 
were counted using Neubauer chamber under the microscope after suitable dilution. 
Adequate no. of cells (5 million) were added in 12 well plates (NUNC cell culture 
plates), each well containing 1.5 ml of RPMI media (RPMI Glutamax + 10 %FCS + 1 % 
PS). The plates were then incubated for 24 hrs in the incubator at 37°C. After 24/36 hrs 
of the incubation, fresh media was replaced for the old media by careful removal of the 
supernatant. Then the cells were stimulated with ligands or media. The plates were again 
incubated for 20-24 hrs at 37°C. After incubation the supernatants were carefully isolated 
in microcentrifuge tubes.  
The cells from each well were lysed using the required amount of RLT buffer containing 
10 µl/ml of -mercaptoethanol (350 µl per well) and collected in DEPC treated sterile 
Eppendorff tubes and stored immediately at –80°C, which were later used for RNA 
isolation. The sups were separated from the residual amount of cells by centrifuging it at 
6000 rpm for 10 min. and immediately stored them at –20°C. These supernatants were 
analyzed for the various cytokines, and chemokines by ELISAs. 
 
3.1.4. Cell culture conditions and cytokine ELISAs 
 
Flt-3 derived bone marrow dendritic cells and cell culture plate adherent spleen 
monocytes (from MRLlpr/lpr mice), processed and cultured as described above. Spleen 
monocytes were treated with medium control or imiquimod 3 µg/ml, RNA40 30 µg/ml 
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along with DOTAP (1µg/5µg) (Roche, Mannheim, Germany), and pI:C-RNA 30 µg/ml 
for 24 hours. Tlr9 ligand B-type CpG-DNA-1668 at a concentration of 1 µg/ml was used 
as a positive control in selected cases. After a period of 24 hours incubation culture 
supernatants were collected for cytokine measurements and cells were prepared for flow 
cytometric analysis. Dendritic cells and spleen monocytes were stimulated as above for 
24 hours and cells were harvested for RNA isolation as described above. J774 mouse 
macrophages (American Type Culture Collection, Rockville, MD, USA) were grown in 
RPMI 1640 containing 1mM HEPES, 10% heat-inactivated bovine serum, 100 units/ml 
penicillin and 100µg/ml streptomycin (Biochrom KG, Berlin, Germany). A murine 
mesangial cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
Biochrom KG, Berlin, Germany) supplemented with 2.5% fetal calf serum and 1% 
penicillin-streptomycin 100 U/ml and 100 µg/ml, respectively. Cells were incubated for 
24 hours without serum supplements before stimulation. Cytokine levels were determined 
using commercial ELISA kits: Il-6, Il-12p70, Il-12p40, Mcp-1 (all OptEiA, BD 
Pharmingen), Tnf-alpha (Biolegend, San Diego, CA, USA), Ifn- (PBL Biomedical 
Labs, USA) following the protocol provided by the manufacturers.  
 
The protocol for ELISAs in brief was as follows  
The NUNC ELISA plate wells were captured overnight at 4°C with the capture antibody 
in coating buffer. Next day the wells were washed 3 times with the washing buffer as 
given in protocol for 3 times and blocked with the blocking solution or assay diluent for 1 
hour or as specified. Again the washings were repeated 3 times followed by addition of 
standards, samples and sample diluent as blank into the wells of tap dried plate and 
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incubated at RT for 2 hours and followed by washings for 5 times or as specified and 
then addition of HRP/AP conjugated secondary antibody diluted in assay diluent. The 
wells were washed again for 5-7 times or as specified and incubated with the 100 µl of 
substrate A and B (1:1 mixture) for 25-30 min in dark to develop colour. The reaction 
was stopped by addition of 100 µl 1 M H2SO4. The reading of the absorbance was taken 
at 450 nm and the reference wavelength was 620 nm using a spectrophotometer 
(TECAN-Genios Plus). 
 
3.1.5. Flow cytometry 
 
The mesangial cells and J774 macrophages were grown in cell culture and then used for 
the receptor expression analysis by flow cytometry. Cells were carefully removed from 
the culture plates by resuspending them in PBS using 1 ml pipette in a 15 ml Falcon tube 
and washed with PBS (cell culture grade) for 2 times by centrifuging it at 1300 rpm at 4 
°C for 6 min. The cells were maintained on ice from here onwards and approximately 
100, 000 cells were separated into 1.5 ml Eppendorff tubes each in a volume of 300 µl in 
PBS and 5 groups of tubes were used in duplicates for the staining with the Tlr receptor 
antibodies, isotype and unstained. All the groups of tubes were processed at a uniform 
time and with uniform processing conditions. The cells were resuspended in a volume of 
200 µl of cold PBS (sterile) and stained with the primary antibodies for Tlrs and isotype 
antibodies for 40 min by incubating them on ice, followed by washing with PBS for 2 
times. Later the cells were incubated in a volume of 200 µl, with the secondary antibodies 
conjugated with PE or FITC for 30 min. and washed 1 time followed by addition of 
streptavidin-APC, kept on ice for 20 min protected from light from this point onwards. 
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Then the cells were washed for 2 times with PBS, and finally resuspended in special 
transparent FACS tubes (5 ml round bottom poly propylene tubes, FALCON, Franklin 
Lakes, NJ, USA), kept on ice and always protected from light until analysis.  
The following primary antibodies were used to detect Tlrs on mesangial cells and 
macrophages: anti-mouse Tlr3 (1:50, IMG516, Imgenex, San Diego, CA), Tlr7 (1:50), 
anti-mouse Tlr9 (1:50, IMG516, Imgenex, San Diego, CA). A biotinylated rabbit anti-
mouse IgG antibody (1:100) and streptavidin-APC (1:100, BD Pharmingen) was used for 
detection and a rabbit IgG (BD pharmingen) was used as isotype control.  
 
3.1.6. RNA isolation, cDNA synthesis and real time RT-PCR 
  
A. Isolation of RNA from cultured cells 
Cell lines as well as primary cell cultures in stimulation experiments were harvested for 
RNA isolation using RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to 
the protocol provided. Firstly, adherent cells to be harvested from 6 well culture plates 
were washed with sterile PBS to remove residual medium after collection and the wash-
through was aspirated. 350 µl RLT buffer containing 10µg/ml beta-mercaptoethanol was 
added directly over adherent cells on the plate surface and pipetted vigorously so as to 
lyse cells. This produced a viscous fluid which was collected and placed in 
microcentrifuge tubes and frozen at –80 °C until RNA isolation. At the time of RNA 
isolation the samples collected were thawed, 350 µl of 70 % ethanol made in 1% Diethyl 
pyrocarbonate treated water (DEPC water) was added to it and mixed well.  This mixture 
was then loaded onto RNeasy mini columns held in 2 ml collection tubes and centrifuged 
at 8000 g for 30 seconds. The flow-through was discarded and the columns were loaded 
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with 700µl of buffer RW1 and centrifuged at 8000 g for 30 seconds. The collection tubes 
were discarded together with the flow-through and the columns were transferred to fresh 
2 ml collection tubes and 500 µl of Buffer RPE was pipetted onto the column, was 
centrifuged at 8000 g for 30 seconds and the flow-through was discarded. This step was 
repeated again and the column was rendered dry by centrifugation, placed in a 1.5 ml 
fresh collection tube, 40 µl of RNase free water was pipetted directly on the silica-gel 
membrane and was centrifuged to collect the RNA solution. No quality check was 
necessary in case of the kit isolation, as empirically the RNA obtained upon kit isolation 
was of good quality standards.  
B. Isolation of RNA from tissues 
 
The RNA isolation protocol was suitably modified from Chomczynski’s method 
(Chomczynski 1987). 3 ml of solution D containing 10µl of beta-mercaptoethanol/ml was 
taken in a 15 ml Falcon tube, to which a small piece of tissue from which RNA had to be 
isolated, was placed. The tissue was homogenised using ULTRA-TURRAX T25 (IKA 
GmbH, Staufen, Germany) at speed level 2 and placed on ice. To this 300µl 2M sodium 
acetate solution was added and mixed gently, followed by addition of 3 ml Roti-Aqua-
Phenol (Carl Roth GmbH, Karlsruhe, Germany) and gentle mixing. A 1.6 ml mixture of 
chloroform/isoamyl alcohol (49:1) was added to the contents of the Falcon and vortexed 
for 20 seconds untill a milky white suspension resulted. The Falcon tube was then placed 
on ice for 15 min and centrifuged at 4000 g at 4 °C. The upper phase (approximately 3 
ml) was collected carefully in a fresh Falcon tube, to which 3 ml isopropanol was added, 
incubated for 30 minutes at –20° C and centrifuged for 15 minutes at 4000 g at 4 °C. The 
supernatant was then discarded carefully to avoid loss of pellet and the Falcon tube was 
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inverted on a tissue paper to drain of the remaining isopropanol. The pellet was then 
dissolved in 0.5 ml solution D and the solution was transferred to a fresh DEPC-treated 
tubes and 0.8 ml Isopropanol was added to it, mixed and placed at –20 for 30 minutes. 
This was followed by centrifugation for 15 minutes at 4000 g at 4 °C, the supernatant was 
discarded carefully to retain the pellet. The pellet was then washed with 80 % ethanol 
made in DEPC water, and vortexed again for 15 minutes at 4000 g at 4 °C. The 
supernatant was discarded and the tubes were inverted to drain of residual ethanol and the 
semi-dried pellet was dissolved in 100 µl DEPC water. A 10µl aliquot was used for the 
quality check and remaining RNA solution was stored at -80 °C until cDNA synthesis. 
The RNA was quantified and quality was determined by taking 2µl of the RNA solution 
diluted 50 times in DEPC water for calculating ratios 260/280 nm spectrophotometric OD 
measurement. The formula used was extinction x dilution to obtain number of µg/ml of 
RNA per sample and a ratio value approximately close to 1.9 was considered to be of 
acceptable quality. Further quality check (if necessary) was performed using a denaturing 
RNA gel, ran at 70-100 V for 1 hour and the gel was then read on a gel documentation 
apparatus.  
 
C. cDNA synthesis and real-time RT-PCR   
The RNA samples isolated according to the procedure detailed above were diluted in 
DEPC water to a concentration of 1µg/20µl. A master mix was prepared with reagents 
including 9 µl of 5x buffer (Invitrogen, Karlsruhe, Germany), 1µl of 25mM dNTP 
mixture (Amersham Pharmacia Biotech, Freiburg, Germany), 2 µl of 0.1 M DTT  
(Invitrogen, Karlsruhe, Germany), 1 µl of 40U/µl RNasin (Promega, Mannheim, 
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Germany), 0.5µl of 15µg/ml linear acrylamide (Ambion Ltd, Cambridgeshire, UK), 0.5µl 
of Hexanucleotide (Roche, Mannheim, Germany), 1µl of Superscript (Invitrogen, 
Karlsruhe, Germany) or ddH2O in case of the controls. The master mix was made to a 
volume of 15µl and added to 2µg/30µl RNA samples were taken in separate DEPC 
treated microcentrifuge tubes, which were mixed and placed at 42 °C on a thermal shaker 
incubator for 1 hour. After 1 hour the cDNA samples were collected and stored at -20 °C 
until use for real-time RT-PCR analysis. The cDNA samples prepared as described above 
were diluted 1:10 a dilution for the real-time RT-PCR. The real-time RT-PCR was 
performed on a TaqMan® ABI Prism 7000 or 7700 (Applied Biosystems, Darmstadt, 
Germany). The quantitative PCR for mRNA is based on the employment of sequence-
specific primers and likewise sequence-specific probes. The latter is tagged at both ends 
with a fluorescent molecule. The quencher absorbs TAMRA (at the 3'-End) the 
fluorescence of the other reporter tagged material such as FAM or VIC at the 5'-End. The 
TaqMan® universal PCR master mix (Applied Biosystems, Darmstadt, Germany) 
contained Taq polymerase possessing a 5'3' polymerase activity and a 5'3 ' 
exonuclease activity. During the elongation phase of the PCR, specifically bound probe 
was hydrolyzed by the exonuclease and the 5'-tag was set free. With every newly 
synthesized DNA strand fluorescent tag material was set free and the resulting 
fluorescence was measured at 488nm. The resulting fluorescence signal is directly 
proportional to the quantity of DNA synthesized. The CT value (= "Cycle Threshold") 
was computed for each sample. This is the cycle number, with which the reporter 
fluorescence signal breaks through a user-defined threshold. The TaqMan® universal 
PCR master mix containing, the forward primers and Reverse primers (final 
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concentration of 300 nM) and the probe (final concentration of 100 NM) was placed on 
ice. In the TaqMan® universal PCR master mix contained are PCR buffers, dNTPs and 
the AmpliTaqGold® previously mentioned (Taq polymerase without 3'  5' exonuclease 
activity). 18µl of the mastermix was pipetted into each well of a 96-well plate and 2µl of 
template (DNA dilution) was added to each of these wells. The plate was sealed and 
centrifuged at 280 xg and analyzed using TaqMan® ABI PRISM 7000 or 7700. For the 
TaqMan® RT-PCR the following temperature settings were used: The first incubation 
was carried out for 2 minutes at 50°C followed by 95°C for 10 minutes so as to activate 
the polymerase. Templates were amplified during 40 cycles each comprising 15 seconds 
incubation at 95°C followed by 1 minute incubation at 60°C. The RT-PCR for the 
housekeepers (18S rRNA or GAPDH) was carried out under similar conditions. The CT 
values were recorded using the ABI PRISM Sequence Detection software (version 1.0) 
and the results were evaluated in relation the respective housekeepers. In all cases 
controls consisting of ddH2O were negative for target and housekeeper genes. 
Oligonucleotide primer (300 nM) and probes (100 nM) were from Applied Biosystems 
(Darmstadt, Germany):  
Primers for Ccl2, Ccl5, and 18s rRNA were predeveloped TaqMan assay reagent from 
PE Biosystems.  
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Table  5. Probes used for real-time RT-PCR 
 
 Accession-
number 
Sequence 
Tlr3 
 
 
AF355152, Forward primer:   5’- CGAAAGT-TGGACTTGTCATCAAATC-3’ 
Reverse primer:   5’-ACTTGCCAATTGTCTGGAAACAC–3’    
6 FAM :               5’-CACTTAAAGAGTTCTCCC–3’           
Tlr7 
 
AY035889 Forward primer:  5’-TGCCACC-TAATTTACTAGAGCTCTATCTTTAT-3’ 
Reverse primer:   5’-TAGGTCAAGAACTTGCAACTCA-TTG– 3’ 
6 FAM :               5’ - CCAAGAAAATGATTTTAATAAC –3’     
Tlr9 NM 031178 Forward primer:   5’-CAATCTGACCTCCCTTCGAGTACTT-3’ 
Reverse primer:   5’-GCCACATTCTATAC-AGGGATTGG–3’ 
6 FAM :               5’- ATTGCCGTCGCTGCGACCATG –3’ 
 
 
 
 
3.1.7. Statistical analysis 
 
Statistics were done using GraphPad Prism (4.03 version). Data were expressed as mean 
 SEM. Data were analysed using unpaired two-tailed t-test for comparison between two 
groups. One-way ANOVA followed by post-hoc Bonferroni`s test was used for multiple 
comparisons. For nonparametric analysis of two groups Two-tailed Fisher’s exact test 
and Mann Whitney U test were performed.  
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3.2. Materials and Methods- Part 2 
 
3.2.1. Animals and experimental protocol 
 
Five week old female MRL-lpr/lpr or MRL/WT mice were obtained from Harlan 
Winkelmann (Borchen, Germany) and maintained throughout in filter top cages under a 
12 hour light and dark cycle. Autoclaved water and standard chow (Sniff, Soest, 
Germany) were available ad libitum. At 8 weeks of age MRL/WT and MRL-lpr/lpr mice 
were divided randomly into 2 groups of five mice that received intraperitoneal injections 
of the following compounds on every alternate days: Saline or 25 μg imiquimod (Sequoia 
Research Products Ltd, Oxford, UK) in 100 μl 0.25% sodium acetate (Merck, Germany). 
All mice were sacrificed by cervical dislocation at the end of week 10 of age. The 
experimental procedure had been approved by the local government authorities. 
 
3.2.2. Evaluation of glomerulonephritis 
 
Blood and urine samples were collected from each animal at the end of the study period. 
Urine albumin concentration was determined using ELISA kits by Bethyl labs 
(Montgomery, TX, USA). Urinary creatinine concentrations were determined using an 
automatic autoanalyzer (Integra 800, Roche Diagnostics, Germany). Serum dsDNA 
autoantibodies were determined by ELISA following the protocol mentioned before in 
part I (using ELISA kits by Bethyl labs). From all mice, kidneys were fixed in 10% 
buffered formalin, processed, and embedded in paraffin. Two μm sections for periodic 
acid-Schiff stains were prepared following routine protocols. The severity of the renal 
lesions was graded using the indices for activity and chronicity as described for human 
lupus nephritis (Austin et al, 1984) as described before in part 1.  
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3.2.3. Cell culture conditions and cytokine ELISAs 
Bone marrow-derived dendritic cells were isolated from MRL/WT and MRL-lpr/lpr 
mice, processed, and cultured as described in part I. Cells were stimulated with pI:C 
RNA 30 μg/ml, imiquimod 3 μg/ml, CpG-ODN 1 μg/ml or medium control for 24 hours. 
Cytokine levels were determined in cell culture supernatants using ELISA kits for IL-6, 
IL-12p40 (OptEiA, BD Pharmingen), and IFN-α (PBL Biomedical Labs, USA). ELISAs 
were performed according to the protocol mentioned in part 1. 
 
3.2.5. Isolation of primary B cells from the spleen of MRL-lpr/lpr and MRL/WT mice 
B Cell Isolation Kit (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) was used 
for the isolation of B cells from spleens of female MRL-lpr/lpr or MRL/WT mice 
following the manufacturer’s protocol with some additions and using ice cold conditions 
and solutions as follows:  
Spleens were isolated from 2 female mice of either MRL-lpr/lpr or MRL/WT of 6-8 
weeks of age after sacrificing them by cervical dislocation, using all sterilized materials 
and sterile conditions in an aseptic hood with HEPA filters. Spleen was collected in a 
sterile Petri plate containing the 2-3 ml of ice-cold media (RPMI+ 10 %FCS + 1 % PS) 
on ice. Then it was mashed using forceps in the petriplate itself and broken into fine 
pieces of tissues. Then the cell suspension was collected in a 15 ml Falcon tube using 1 
ml pipette and centrifuged at 1600 rpm at 4°C for 6 min. The supernatant was decanted 
and pellet was resuspended in 4 ml of sterile 0.3M NH4Cl solution in water and kept at 
room temperature for 5 min. Then it was Centrifuged at 1600 rpm at 4°C for 6 min. 
Supernatant was decanted and pellet was resuspended in ice cold (cell culture grade) PBS 
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and centrifuged at 1600 rpm at 4°C for 6 min. Now the cell suspension was passed 
through the 30 µm sterile pre-separation filter from Miltenyi biotec to obtain single cell 
suspension. Then it was centrifuged as above and the pellet was resuspended in 2 ml of 
buffer (PBS, pH 7.2 containing 0.5% BSA and 2 mM EDTA) (the buffer was prepared 
freshly and degassed by sonication, kept ice cold). A part of this cell suspension (100 µl) 
was used for counting the cell number after suitable dilution using Neubar’s chamber. 
Then the cells were centrifuged at 300 g for 10 min. the supernatant was pipetted out and 
pellet was resuspended in 40 µl of buffer per 107 total cells. Then 10 µl of biotin antibody 
cocktail per 107 total cells was added and mixed with gentle pipetting and incubated for 
10 min at 4-8 °C. Then 30 µl of buffer and 20 µl of anti biotin microbeads per 107 total 
cells was added, mixed and incubated for 15 min at 4-8°C. Later the cells were washed 
with buffer with 10-20 X labelling volume and centrifuging at 300 g for 10 min. the 
supernatant was pipetted off completely and the pellet was resuspended in 500 µl of 
buffer per 108 total cells. MACS LS column was placed in MiniMACS separator with 
column adapter and the column was rinsed with 500 µl of buffer. The cell suspension was 
applied in suitable amount of buffer onto the column (500-1000 µl). The cells were 
passed through the column and the effluent was collected as fraction with unlabelled 
cells, representing enriched B cell fraction. The column is washed with the appropriate 
amount of buffer (3 X 500 µl) and entire effluent is collected in same tube.  
The cells count was done after suitable dilution in buffer and then the cells were plated in 
a 24 well or 96 well plate for stimulation or proliferation (1 x 105 or 3 x 105 cells per 
well) respectively. Purity was determined by FACS analysis using CD45/B220-PE or Rat 
IgG2a as an isotype (BD Biosciences, Hamburg, Germany) revealed 97 % B cells after 
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each isolation. 
 
3.2.6. B-cell proliferation assay 
Proliferation of B-cells was assessed using CellTiter 96 Proliferation Assay (Promega, 
Mannheim, Germany). In brief, 1 x 105 B-cells were incubated in 96-well plates in 100 µl 
RPMI medium containing 10 % FCS, 100 units/ml penicillin, and 100µg/ml streptomycin 
(Biochrom KG, Berlin Germany) with Tlr ligands as above for a period of 72 hours. To 
each well 20 µl CellTiter 96 Aqueous One Solution (Promega) was added and incubated 
at 37°C for 4 hours. The optical density was measured at 492 nm using a 
spectrophotometric plate reader. 
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3.3 Materials and Methods- Part 3 
3.3.1. Phosphothioate IRS oligodeoxynucleotides (ODN) and other Tlr ligands  
The following endotoxin-free ODN purchased from TIB Molbiol, Berlin, Germany were 
used for in vitro or in vivo studies: IRS661: 5'-TGCTTGCAAGCTTGCAAGCA-3'; 
IRS954: 5'- TGCTCCTGGA-GGGGTTGT-3'; CpG-DNA 1668: 5`-
TCGATGACGTTCCTGATGCT-3`. Control ODNs were 5‘-TCCTGCAGGTTAAGT-3‘ 
and 5’-TCCTGGCGGAAAAGT-3‘. Poly (I:C)-RNA, LPS ultra-pure were purchased 
from Invivogen (San Diego, USA) and Imiquimod was purchased from Sequoia Research 
Products Ltd (Oxford, UK).  
 
3.3.2. Studies with spleen monocytes 
Adherent spleen monocytes were prepared from 10 week old female MRL-lpr/lpr mice 
and kept in culture as previously described in part 1 of materials and methods. Cells were 
stimulated with either medium or various concentrations of imiquimod or CpG-DNA 
1668 or LPS or poly (I:C) with or without inhibitory oligos, IRS661 or IRS954 as 
indicated. Supernatants were harvested after 24 hours for ELISA. 
 
3.3.3. Animal studies and experimental protocol 
Ten weeks old female MRL-lpr/lpr mice (stock  000485) were obtained from Jackson 
Laboratories (Bar Harbor, MA, USA) and were kept in filter top cages under a 12 hour 
light and dark cycle. Autoclaved water and standard chow (Sniff, Soest, Germany) were 
available ad libitum. To assess the distribution of injected IRS661, 100 µg 3'-rhodamine-
labeled IRS661 or IRS954 was injected i.v. in a volume of 100 µl into 16 weeks old 
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MRL-lpr/lpr mice. Tissues were collected 2 hours after injection and subjected to further 
analysis. Different groups of mice were treated with either saline, IRS661 or IRS954 at a 
dose of 40 μg i.p. on alternate days from week 11 to 24 of age. Blood samples were 
collected after 3 hours of the last injection by retroorbital puncture. Mice were sacrificed 
by cervical dislocation under anesthesia. Blood and urine samples were collected from 
each animal at the end of the study period and the urine albumin concentration was 
determined using ELISA kits (Bethyl Labs), urine creatinine was determined as 
previously described (in part 2). All experimental procedures were performed according 
to the German animal care and ethics legislation and had been approved by the local 
government authorities. 
 
3.3.4. Autoantibody analysis 
A. Anti-nuclear antibodies (ANA) 
ANA were determined by incubating serum samples (1:200) with Hep-2 slides 
(Biosystems S.A. Costa Brava, Barcelona, Spain). The fluorescent patterns of ANA were 
classified as homogenous nuclear, speckled nuclear, cytoplasmic and mitotic pattern as 
described (Whichever staining pattern was observed predominant such as 80-90 % of the 
focused areas per well of Hep-2 slide was considered as that class of pattern). The 
secondary antibody used was fluorescein labelled Goat anti mouse IgG (Invitrogen, 
Karlsruhe, Germany) in 1:50 dilution in PBS. Serum of 6-10 week old C57BL/6 mice 
was used as negative control. Homogenous nuclear pattern- entire nucleus stained in a 
continuous manner, Speckled nuclear- staining of nucleus in a speckled manner, like 
many dots in and on the border of the nucleus, mitotic pattern- staining of the nucleus 
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when it is in division stage and can see both the nucleus together. 
 
B. Anti-dsDNA ELISA assay  
NUNC maxisorp ELISA plates were coated with poly-L-lysine (Trevigen, Gaithersburg, 
MD, USA) and followed by mouse embryonic stem cell dsDNA overnight. After 
incubation with mouse serum samples for 2 hours specific secondary antibody IgG, IgG1, 
IgG2a, IgG2b, IgG3 was used for detection of isotype by ELISA (Bethyl Labs, 
Montgomery, TX, USA) following the protocol as mentioned before in Part-1. 
 
C. Crithidia luciliae assay 
Immunofluorescence on specific slides of Crithidia Luciliae (BioRad Laboratories, 
Munich, Germany) was performed with 1:100 dilution of serum in PBS (pH 7) and 
scored for the intensity of kinetoplast DNA from 0 to 4. The secondary antibody used 
was fluorescein labeled Goat anti mouse IgG (Invitrogen, Karlsruhe, Germany) in 1:50 
dilution in PBS (pH 7). For scoring, 0 – considered for no visually detectable 
fluorescence, 1 – considered for mild fluorescent signal from the kinetoplast, 2- 
considered for moderate signal, 3- considered for moderately higher signal, 4- considered 
for very high intense signal. 
 
D. Anti-Sm and anti Sm-RNP 
NUNC maxisorp ELISA plates were coated with Smith (Sm) antigen (stock- 5 mg/ml) 
(Immunovision, Springdale, AR, USA) at a dilution of 1:250. The Sm IgG (Y12) 
antibody (GeneTex, San Antonia, TX, USA) was used for standard curve and the 
  - 64 - 
dilutions were made in PBS. A horseradish peroxidase-conjugated Goat anti-mouse IgG 
(2 mg/ml, Rockland Immunochemicals Research, Gilbertsville, PA, USA) was used as 
secondary antibody at a dilution of 1 µl in 50 ml in PBS (pH 7). The same procedure was 
followed for anti-SmRNP as for anti-Sm except the ELISA plates were captured with 
Sm-RNP complex (1000 units/ml) (Immunovision) at a dilution of 1:250 instead of Sm 
antigen. For the ELISAs, equal volumes of Substrate A and B were mixed for the 
required number of wells and added for reaction completion (100 µl per well) and kept 
for 30 min in dark and followed by 100 µl of 1M H2SO4 for stopping the reaction. The 
reading of the absorbance was taken at 450 nm using spectrophotometer (TECAN). 
 
E. Rheumatoid factor 
NUNC maxisorp ELISA plates were coated with rabbit IgG at a concentration of 10 
µg/ml (Jackson Immunoresearch, West Grove, PA, USA) overnight at 4° C. Serum 
samples were diluted 1:100 in PBS (pH 7), 10 week old C57BL/6 mouse serum was used 
as negative control. HRP conjugated goat anti-mouse IgG (2 mg/ml, Rockland 
Immunochemicals Research, Gilbertsville, PA, USA) was used as secondary antibody at 
a dilution of 1 µl in 50 ml of PBS (pH7). Substrate A and B were used for reaction 
completion for about 25-30 min to develop the colour in dark and followed by 1M H2SO4 
for stopping the reaction. The absorbance was measured at 450 nm with reference 
wavelength as 620 nm at spectrophotometer as mentioned before. 
 
3.3.5. Flow cytometry for spleen cells 
Spleens were isolated from the treated MRL-lpr/lpr mice of each group (IRS661, IRS954, 
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Saline) after sacrificing it, and 3 subgroups were made by pooling 3, 3 & 4 spleens from 
each treatment group. Spleen was collected in a sterile Petri plate containing the 2-3 ml of 
ice-cold media (RPMI+ 10 %FCS + 1 % PS) on ice. Then it was mashed using forceps in 
the petriplate itself and broken into fine pieces of tissues. Then the cell suspension was 
passed through 70 µm plastic filter (BD biosciences) using the 1 ml pipette and collected 
in a 15 ml Falcon tube with pipette and centrifuged at 1600 rpm at 4°C for 6 min. The 
supernatant was decanted and the pellet was resuspended in 4 ml of sterile 0.3M NH4Cl 
solution and kept at room temperature 5 min. Then it was Centrifuged at 1600 rpm at 4°C 
for 6 min. Supernatant was decanted and pellet was resuspended in ice cold (cell culture 
use) PBS and centrifuged at 1600 rpm at 4°C for 6 min. Pellet was resuspended in ice 
cold PBS and passed through 70 µm plastic filter and collected in new Falcon and again 
centrifuged as before. The pellet was resuspended in PBS (2-4 ml) and the no. of cells 
were counted using Neubar’s chamber under the microscope after suitable dilution. The 
cells suspension was suitably diluted to obtain 1 million cells/ml, later cells were 
subdivided into different eppendorff tubes in a volume of 200 µl for different staining 
with the isotype, T cell marker, or unstained. Cells suspension in eppendorff tubes were 
incubated with labelled antibody for 30 min in dark, followed by washings (2 times) and 
then transfer in special FACS tubes in a volume of 400 µl of PBS and protected from 
light until flow cytometry analysis. 
The following antibodies were used to identify T cell subsets: FITC-labelled hamster 
anti-mouse CD3 (clone 145-2C11, BD, Biosciences, Heidelberg, Germany), APC-
labelled rat anti-mouse CD4 (clone RM4-5, BD), PerCP-labelled rat anti-mouse CD8 
(clone 53-6.7, BD), PerCP-labelled rat IgG2a (clone R35-95, BD), and APC-labelled rat 
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IgG2a (clone R35-95, BD), PE-labelled rat IgG2a (clone R35-95, BD) were used as 
isotype controls, respectively.  
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4.0. Results  
4.1. Results- Part 1 
 
4.1.1 Toll like receptor 7 expression in experimental lupus nephritis 
Based on the previous studies from our lab, it was found that the expression of Tlr7 is 
increased in the kidneys of 20 wks old female MRL-lpr/lpr mice compared to their young 
counterparts (Figure 6). In order to localize the source of renal Tlr7 expression a 
polyclonal antibody specific for murine Tlr7 and performed double staining for either 
ER-HR3 or CD11c in renal sections of 16 weeks old MRL-lpr/lpr mice. Approximately 
30% of interstitial ER-HR3 macrophages and CD11c dendritic cells (ratio 90%: 10% 
respectively) stained positive for Tlr7 (Figure 7). Staining for Tlr7 appeared in a speckled 
pattern indicating that Tlr7 is localized in an intracellular compartment. Intrinsic renal 
cells were negative for Tlr7 and the macrophages found to be present in the glomerular 
compartment were rarely positive for Tlr7. Together these data suggest that in nephritic 
kidneys of MRL-lpr/lpr mice, Tlr7 is expressed mainly by infiltrating interstitial 
macrophages but not by intrinsic renal cells. 
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Figure 6.  Tlr7 expression in MRL-lpr/lpr mice. Expression of Tlr mRNA was assessed 
by real-time RT-PCR in duplicates using RNA isolated from spleens and kidneys from 7 
MRL-lpr/lpr mice each at 5 weeks and 20 weeks of age as described in methods. Tlr 
mRNA expression is expressed as ratio to the respective 18S rRNA expression  SEM. 
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Figure 7.    Tlr7 immunostaining and uptake of labelled ssRNA in kidneys of MRL-
lpr/lpr mice. A:  mTlr7 specific antibody was used on renal sections of 18 week-old 
nephritic MRL-lpr/lpr mice. A PE-labelled secondary antibody was used for detection. 
Positive signals colocalized with ER-HR3 positive macrophages or CD11c positive 
dendritic cells, both detected by a FITC-labelled secondary antibody. B: Rhodamine-
labelled ssRNA 40 was intravenously injected to 18 weeks old MRL-lpr/lpr mice and 
kidney tissue was harvested two hours later. Fluorescence imaging of frozen sections 
showed uptake of ssRNA 40 (red) into ER-HR3 positive macrophages (green). C: 
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Costaining of rhodamine-labelled cells (red) for Tlr7 (green) demonstrates uptake of 
RNA 40 into Tlr7 positive cells. Original magnification of all images 530x.  
 
 
4.1.2. In vivo localization of labelled ssRNA after IV injection in MRL-lpr/lpr mice 
In order to examine whether circulating ssRNA localizes to nephritic kidneys of MRL-
lpr/lpr mice, rhodamine-labeled ssRNA40 was injected intravenously to 20 weeks old 
MRL-lpr/lpr mice. Consistent with Tlr7 immunostaining in the kidney, the labelled 
ssRNA was found in infiltrating cells in a granular intracellular staining pattern (Figure 
7). Double labelling with an ER-HR3-specific antibody identifying these cells as renal 
macrophages (Figure 7). MRL-lpr/lpr mice injected with rhodamine only did not localize 
in the kidney. Double labelling for Tlr7 confirmed that injected ssRNA was taken up into 
Tlr7 positive cells (Figure 7). MRL-lpr/lpr mice injected which rhodamine only did not 
localize in the kidney. Taken together, in kidneys of MRL-lpr/lpr mice injected ssRNA 
colocalizes in an intracellular granular pattern with Tlr7 positive cells, i.e. infiltrating 
macrophages and DCs, but not with intrinsic renal cells.  
    
4.1.3. In vitro stimulation of cultured macrophages and mesangial cells by Tlr7 ligand 
In order to confirm the respective Tlr7 expression, murine cell lines for macrophages 
(J774) and mesangial cells were cultured. Under basal culture conditions mesangial cells 
expressed Tlr3 mRNA, while mRNAs for Tlr7, and –9 were not detected (Figure 8). By 
contrast, J774 macrophages expressed all three receptors (Figure 8). The subcellular 
localization of Tlr3, -7, and -9 was assessed by flow cytometry. In mesangial cells Tlr3 
and in macrophages Tlr3, -7, and -9 were expressed intracellularly while surface 
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expression was absent (Figure 8). Next it was questioned whether mesangial cells and 
macrophages respond to microbial nucleic acids corresponding to their specific Tlr 
expression profile. Both cell types were stimulated with synthetic mimics of microbial 
nucleic acids: pI:C-RNA (Tlr3) or imiquimod or RNA40 (Tlr7), or CpG-DNA-1668 
(Tlr9). In accordance with their respective Tlr expression profile, mesangial cells 
produced the CC-chemokine MCP-1 (CCL2) only after exposure to mimics of viral 
dsRNA, whereas J774 macrophages responded to all Tlr agonists tested (Figure 8). 
Together, these data indicate that macrophages, but not mesangial cells, express Tlr7 in 
an intracellular compartment and produce CCL2 upon exposure to ssRNA or imiquimod 
in vitro.  
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Figure 8.  Nucleic acids activate cultured mesangial cells and J774 macrophages 
consistent with their respective Tlr expression profile. Murine mesangial cells and J774 
macrophages were cultured as described in methods. A: Expression of Tlr mRNA was 
assessed by real-time RT-PCR in duplicates using RNA isolated from cultured cell lines. 
Tlr mRNA expression is expressed as ratio to the respective 18S rRNA expression ± SEM 
(* p < 0.05). B: Flow cytometry for Tlrs before and after permeabilization for 
intracellular staining was performed as indicated. Expression of Tlr (solid line) is 
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demonstrated by a fluorescence shift compared to the isotype control antibody (dotted 
line). C: Cultured cells were incubated with either pI:C RNA, imiquimod (IMI) or RNA 
40 or CpG-DNA or standard medium without supplements for 24 hours as indicated. 
CCL2 production was measured in supernatants by ELISA. Results shown are 
representative of two comparable experiments each performed in duplicate. 
 
 
4.1.4. Primary spleen monocytes and dendritic cells isolated from MRL-lpr/lpr mice 
3 positive macrophages and CD11c positive 
responds to stimulation with Tlr7 agonists  
As Tlr7 appears to be expressed by ER-HR
dendritic cells in nephritic kidneys of MRL-lpr/lpr mice, hence in order to characterize 
the factors produced by these cells in response to agonists of Tlr7 in comparison to other 
nucleic acid-like Tlr agonists, in-vitro experiments were planned. Spleen monocytes and 
bone-marrow dendritic cells were isolated from MRL-lpr/lpr mice as described in 
methods. ER-HR3 positive population comprised approximately 90% of the spleen 
monocytes, which were found to be negative for CD11c. Likewise, approximately 85% 
of the bone marrow derived dendritic cells were found to be positive for CD11c, which 
were found to be negative for ER-HR3 as determined by flow cytometry. Both cell types 
were incubated with either pI:C-RNA or RNA40 or imiquimod or CpG-DNA-1668. In 
spleen monocytes both, RNA40 and imiquimod, induced production of IL-6, IL12p70, 
IFN-α, and MCP-1 (CCL2) (Figures 9A-D). In bone marrow-derived dendritic cells the 
observed responses were similar except for increased IL12-p70 and IFN-α production 
upon exposure to pI:C RNA (Figure 9A-D) as compared to stimulation of spleen 
monocytes.  These data suggest that Tlr7 agonists induce the production of IL-12p70, IL-
6, CCL2, and IFN-α in both spleen monocytes and dendritic cells isolated from MRL-
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lpr/lpr mice.  
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 Figure 9. Tlr7 agonists activate ER-HR+ monocytes and CD11c+ dendritic cells 
isolated from MRL-lpr/lpr mice. ER-HR3+/CD11c- spleen monocytes and ER-HR3-
/CD11c+ dendritic cells (DCs) from spleens and bone marrows (BM) respectively of 
MRLlpr/lpr mice were cultured and incubated with either pI:C-RNA or RNA40 or 
imiquimod or CpG-DNA or standard medium for 24 hours as indicated. IL-6 (A), IL-
12p70 (B), CCL2/MCP-1 (C), and IFN-α (D) were measured in supernatants by ELISA. 
Results shown are from one of three comparable experiments. For each experiment cells 
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were pooled from 3 mice. Values represent means ± SEM, n.d. = non detectable. 
 
 
4.1.5. Imiquimod increases serum IFN-alpha, IL-6, and IL-12p70 levels in MRLlpr/lpr 
mice. 
Circulating IFN-alpha, IL-6, and IL-12p70 levels are markers of disease activity in lupus. 
Thus, having demonstrated the effect of Tlr7 ligation on IFN-alpha, IL-6, and IL-12p70 
secretion in antigen-presenting cell subsets isolated from MRLlpr/lpr mice in vitro, 
serum levels of these factors were studied 6 hours after intraperitoneal injection of 25 µg 
of imiquimod or vehicle or saline to 16 weeks old MRLlpr/lpr mice. Injection of 
imiquimod significantly increased serum levels of IL-12p70, IL-6, and IFN-alpha in 
MRLlpr/lpr mice as compared to vehicle-injected controls (Figure 10).  
 
 
 
 
 
Figure 10. Serum IFN-, IL-12p70, and IL-6 levels in MRLlpr/lpr mice. Serum was 
obtained from 16 weeks old MRLlpr/lpr mice 6 hours after the first intraperitoneal 
injection of either saline or vehicle or 25 µg imiquimod as indicated (n=5-10). Serum 
levels were determined by ELISA. Data are mean ±  SEM. * p < 0.05 vs saline. 
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4.1.6. Imiquimod aggravates autoimmune tissue injury in MRL lpr/lpr mice.  
From the above results one would predict that ligation of Tlr7 would be associated with 
more severe autoimmune tissue injury in MRLlpr/lpr mice. Therefore different groups of 
lupus mice were treated with intraperitoneal injections of either 25 µg imiquimod or 
vehicle or saline on alternate days from week 16 to 18 of age. Based on the results of in 
vitro studies with macrophages and dendritic cells, it was hypothesized that Tlr7 ligation 
would trigger local chemokine expression in nephritic kidneys of MRL lpr/lpr mice. 
Thus, immunostaining for CCL2 was performed. Taken together, imiquimod aggravated 
autoimmune tissue injury in MRLlpr/lpr mice associated with increased local expression 
of CCL2 in areas of inflammatory cell infiltrates and tissue damage in nephritic kidneys 
of MRLlpr/lpr mice.  
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 Figure 11. Renal histopathology. A: Renal sections of 18 weeks old MRLlpr/lpr mice 
from all groups were stained with periodic acid Schiff, antibodies for ERHR-3 
(macrophages), CD3 (lymphocytes), and SMA (smooth muscle antigen for 
myofibroblasts) as indicated. Insert in PAS stained sections of imiquimod-treated 
MRLlpr/lpr mice illustrates glomerular tuft necrosis and crescent formation not detected 
in mice of the other groups (Original magnification x400). Inserts in ERHR-3 and CD3-
stained sections show respective glomeruli at a magnification of x530). Images are 
representative for 8-10 mice in each group. B: Renal sections of 18 weeks old vehicle or 
imiquimod-treated MRLlpr/lpr mice were stained for CCL2/MCP-1. Arrows indicate CCL2 
positive glomerular and interstitial cells. Note CCL2 positivity also in tubular epithelial 
cells in imiquimod-treated mice (original magnification x400). Images are representative 
for 5 mice in each group. 
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Table 7. Urinary finding in treated MRLlpr/lpr mice.  
 
  Saline Vehicle Imiquimod 
     
Proteinuria as 
Albumin/creatinine (mg/mg.) 
5.4 ± 2.5  3.3 ± 0.9  17.8 ± 6.2a 
 
Values are means ±  SEM, a p < 0.05 imiquimod vs. Vehicle 
 
 
4.1.7. Imiquimod increases renal immune complex deposition in MRL lpr/lpr mice 
Based on the results of previous studies in our lab it was observed that the activation of 
Tlr9 as well as Tlr3 aggravated lupus nephritis in MRLlpr/lpr mice. Hence, the effects of 
Tlr7 ligation were investigated on serum dsDNA autoantibody levels and glomerular IgG 
deposits in MRLlpr/lpr mice. Imiquimod somewhat increased serum total IgG as well as 
IgG1-, and IgG2a-dsDNA autoantibodies as compared to vehicle-treated MRLlpr/lpr mice 
although this was not statistically significant (Figure 12A). However, imiquimod-treated 
MRLlpr/lpr mice showed increased glomerular capillary and mesangial deposits of total 
IgG, IgG1, and IgG2a (Figure 12B, Table 7). This was associated with increased 
glomerular capillary and mesangial deposits of complement factor C3c in imiquimod-
treated MRLlpr/lpr mice (complement deposit score imiquimod: 2.4 ± 0.3 vs. vehicle: 1.3 
± 0.1, p < 0.01, Figure 12C). Together, imiquimod-induced aggravation of lupus nephritis 
in MRLlpr/lpr mice is associated with increased glomerular immune complex deposition. 
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Figure 12. DNA autoantibodies and immune complex deposits in MRLlpr/lpr mice. A: 
Serum dsDNA autoantibody levels were determined by ELISA (n=5-10). Data are mean ± 
SEM. p was < 0.05 vs vehicle for IgG and both IgG isotypes. B and C: Immunostaining 
for total IgG, IgG1, IgG2a and complement factor C3c were performed on renal sections 
of MRLlpr/lpr mice as described in Methods (original magnification 400x).  
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4.2. Results Part 2 
 
4.2.1 Tlr7 ligand induced effects on spleen and DNA autoantibodies in young MRL 
and MRLlpr/lpr mice 
At 8 weeks of age no structural abnormalities were detected in kidney and spleens of 
MRL wild-type mice as observed using light microscopy. Spleens of age-matched 
MRLlpr/lpr mice displayed lymph follicle hyperplasia with enlarged B-cell zones and 
increased spleen weight (Figure 13A, Figure 14B). Renal morphology did not show any 
abnormalities in MRLlpr/lpr mice of this age. Given the pathogenic role of 
lymphoproliferation and autoantibody production for the pathogenesis of lupus nephritis 
it was first tested whether exposure to imiquimod induces splenomegaly and the 
production of DNA autoantibodies in young MRL or MRLlpr/lpr mice. Serum dsDNA 
autoantibodies were determined by ELISA in all groups of mice at 10 weeks of age. In 
saline-treated MRL wild-type mice, serum dsDNA antibodies were absent and 
imiquimod did not induce significant levels of dsDNA IgG autoantibodies. In contrast, 10 
week old saline-treated MRLlpr/lpr mice had detectable levels of total IgG and IgG1 
dsDNA antibodies (Figure 13B). Exposure to imiquimod increased serum levels of total 
IgG dsDNA antibodies. However the ELISA kits for detection of IgG2a and IgG2b dsDNA 
antibodies were observed to be less sensitive compared to total IgG ELISA kit. 
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 Figure 13. Lymphoproliferation and serum dsDNA autoantibodies in MRL and 
MRLlpr/lpr mice. A: Spleen weights were assessed at time of sacrifice at 10 weeks of age 
in MRL and MRLlpr/lpr mice treated with saline or imiquimod, as indicated (n=5). B: 
Serum levels of dsDNA autoantibodies of the IgG, IgG1, IgG2a and IgG2b isotypes were 
determined by ELISA. Imi = imiquimod. Data are mean  SEM. * p < 0.05 vs. saline, #  p 
< 0.05 vs. MRL wild-type mice. n.d. = not detectable. 
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4.2.2 In vivo and in vitro B-cell responses by Tlr7 ligand in MRL and MRL-lpr/lpr 
mice 
The potential of microbial nucleic acids to induce autoantibody production in MRLlpr/lpr 
mice may be linked to their potential to activate B-cells. The proliferation of medium-
treated cultured primary B-cells isolated from MRL and MRLlpr/lpr mice was 
comparable (Figure 14A). Consistent with previously published data, the effect of 
imiquimod was less prominent in the absence of additional costimuli and did not 
significantly affect the proliferation of B-cells of either mouse strain. Imiquimod-induced 
IL-12p40 production was less potent, but in the presence of 5000 u/ml IFN-α imiquimod 
markedly induced IL-12p40 (Figure 14C). Thus, by virtue of its effect on spleen size and 
autoantibody production imiquimod per se was not found to be a potent B-cell mitogen in 
MRLlpr/lpr mice.  
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Figure 14.  B-cells in MRL and MRL-lpr/lpr mice. A: CD19+ B cells were prepared 
from spleens of MRL and MRLlpr/lpr mice and incubated with either pI:C RNA or 
imiquimod or CpG-DNA-1668 or standard medium as indicated. After 72 hours of 
incubation B-cell proliferation was assessed by CellTiter 96 proliferation assay. The 
optical density (O.D.) was read at 490 nm. B: Spleen sections were prepared from mice 
of all groups and stained for B220+ B-cells. Images are representative for 5 mice in each 
group (original magnification x50). C: CD19+ B cells were prepared from spleens of 
MRL and MRLlpr/lpr mice and incubated with either pI:C RNA or imiquimod or CpG-
DNA or standard medium in the presence or absence of 5000 u/ml murine IFN-α as 
indicated. IL-12p40 were measured in supernatants by ELISA after 24 hours of 
incubation with the respective Tlr ligands. Results shown as mean ± SEM from three 
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comparable experiments. * p<0.05 vs medium, n.d. = non detectable. 
 
 
4.2.3. Serum levels of cytokines after challenge with Tlr7 ligand in young MRL and 
MRLlpr/lpr mice 
Circulating IL-12p40, IL-6, and IFN- levels are markers of disease activity in lupus. 
Thus, it was questioned to study imiquimod induced changes in the serum cytokine levels 
in 10 weeks old MRL and MRLlpr/lpr mice. Serum IL-12p40, IL-6, and IFN- levels 
were determined at 3, 6, 12, and 24 hours after a single agonist injection in MRL and 
MRLlpr/lpr mice. Baseline levels of all cytokines were low in saline-treated MRL and 
MRLlpr/lpr mice (Figure 15). Il-12p40 was induced by imiquimod in both strains with a 
maximum at 6 hours after injection (Figure 15). Serum IFN- levels were low in all 
groups of mice and did not respond significantly to imiquimod (Figure 15). These data 
suggest that IL-12p40 levels are induced upon exposure to imiquimod. 
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Figure 15. Serum IL-12p40, IL-6, and IFN- levels in MRL and MRLlpr/lpr mice. 
Serum was obtained from 10 weeks old MRL and MRLlpr/lpr mice at different time points 
after single injection with pI:C RNA, imiquimod, and CpG-DNA as indicated (n=5). 
Serum levels were determined by ELISA. Data are mean  SEM. * p < 0.05 vs saline, #  p 
< 0.05 vs. MRL wild-type mice, n.d. = not detectable. 
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4.2.4. Tlr7 mediated activation of primary dendritic cells isolated from MRL and 
MRLlpr/lpr mice 
Dendritic cells coordinate adaptive immune responses during antimicrobial immunity as 
well as autoimmunity. Hence it was examined whether Flt3-ligand-induced, CD11c 
positive ER-HR3 negative dendritic cells prepared from MRL or MRLlpr/lpr mice 
release proinflammatory cytokines when incubated with different doses of either medium 
or pI:C-RNA or imiquimod or CpG-DNA. All three Tlr agonists induced IL-12p40 and 
IL-6 in dendritic cells (Figure 16). Imiquimod and pI:C RNA were less potent in inducing 
IL-12p40 and IL-6 release in dendritic cells from MRL or MRLlpr/lpr mice and higher 
doses of imiquimod did not further increase cytokine release due to cytotoxicity. 
Imiquimod and CpG-DNA but not pI:C RNA induced IFN-α. No differences between 
dendritic cells from MRL and MRLlpr/lpr mice were detected except for high doses of 
CpG-DNA. 
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Figure 16. Activation of dendritic cells isolated from MRL and MRLlpr/lpr mice. ER-
HR3-/CD11c+ dendritic cells were prepared from bone marrows of MRL and 
MRLlpr/lpr mice and incubated with standard medium or different doses of either pI:C-
RNA or imiquimod or CpG-DNA for 24 hours as indicated. IL-12p40, IL-6, and IFN-α 
were measured in supernatants by ELISA. Results were shown as mean ± SEM from three 
comparable experiments, * p<0.05. n.d. = non detectable.  
  - 89 - 
        Table 8. Histological and urinary findings in MRL/WT  and MRLlpr/lpr mice.  
 
 Saline  Imiquimod  
Urinary albumin/creatinine ratio  
  MRL 0.04 ± 0.01  0.07 ± 0.02  
  MRLlpr/lpr 0.07 ± 0.01  0.12 ± 0.09   
 
N = 5 per group, values are mean ± SEM. 
 
 
4.2.5. Imiquimod modulates lupus nephritis in young MRL lpr/lpr and MRL mice 
The induction of DNA autoantibody production could be associated with respective renal 
immune complex deposition and subsequent lupus nephritis. Hence, glomerular immune 
IgG1 and IgG2a deposition were quantified by immunohistochemistry. In MRL wild-type 
mice of all groups glomerular IgG1 and IgG2a deposits were not detected. Saline-treated 
MRLlpr/lpr mice had mild glomerular IgG1 and IgG2a deposits, predominantly in a 
capillary staining pattern (Figure 17). In MRLlpr/lpr mice injections of imiquimod did 
not significantly increase the amount of glomerular IgG1 and IgG2a deposits (Figure 17). 
Glomerular immune complexes cause glomerular damage through local complement 
activation. Glomerular C3 deposits in MRLlpr/lpr mice was hardly detectable in 
imiquimod-treated MRLlpr/lpr mice and absent in MRL wild-type mice (Table 8). 
Immunostaining for CD3 lymphocytes and Mac-2 macrophages in renal sections revealed 
no change in glomerular macrophages in different groups (Figure 17, Table 8). CD3 
lymphocytes were not found at significant numbers in kidneys of MRL and MRLlpr/lpr 
mice. Imiquimod injected mice also had no change proteinuria indicated by urinary 
albumin/creatinine ratio (Table 8). These data indicate that exposure to imiquimod does 
not induce lupus nephritis in MRL wild-type mice.  
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Figure 17. Renal histopathology in MRLlpr/lpr mice.  Renal sections of 10 weeks old 
MRLlpr/lpr mice from all groups were stained with antibodies for IgG2a and Mac-2 
(macrophages), PAS as indicated. Glomeruli are encircled. Images are representative for 
5 mice in each group (original magnification x400).  
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4.3. Results Part 3 
 
4.3.1. Tlr7 blockade with IRS661 inhibits the imiquimod-induced release of IL-6 and 
TNF-α; and Tlr7/Tlr9 blockade with IRS954 inhibits imiquimod- & CpG-ODN-
induced release of IL-6 & TNF-α in spleen monocytes from MRLlpr/lpr mice  
Oligodeoxynucleotides with immunoregulatory sequences (IRS) specifically block Tlr7- 
(IRS661) or Tlr7/Tlr9-mediated interferon-α production (IRS954) in vitro (Barrat et al, 
2005). To ascertain the rational to use these IRS in MRLlpr/lpr mice, spleen monocytes 
from MRLlpr/lpr mice were stimulated with respective Tlr7 or Tlr9 ligands, i.e. 
imiquimod or CpG-ODN-1668. IRS661 dose-dependently blocked imiquimod-induced 
production of IL-6 and TNF-α (Figure 18A, 19A). IRS954 but not IRS661 dose-
dependently inhibited CpG-DNA-induced production of IL-6 and TNF-α (Figure 18B, 
19B). IRS954, but not IRS661, showed significant dose dependent inhibition of IL-6 and 
TNF-α production when the cells were incubated with imiquimod plus CpG-DNA 
(Figure 18C, 19C). By contrast, neither IRS affected IL-6 or TNF-α production induced 
by LPS or pI:C RNA (Figure 18D, 19D). The same set of experiments were repeated for 
the two control oligos. Both the control oligos did not show any inhibition of the IL-6 and 
TNF-α release (Figure 18E-H, Figure 19E-H). These data confirms that IRS661 and 
IRS954 act as specific antagonists for either Tlr7- or Tlr7/Tlr9-induced activation of 
monocytes in vitro.  
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Figure 18. IRS661 and IRS954 specifically block specific TLR ligand induced IL-6 
release in spleen monocytes from MRLlpr/lpr mice in vitro. Spleen monocytes from 
MRLlpr/lpr mice were incubated with imiquimod and IRS661 at different concentrations 
as indicated or standard medium without supplements for 24 hours as indicated. A-C: 
Spleen monocytes were incubated with either imiquimod or CpG-DNA alone or 
imiquimod plus CpG-DNA. D: Cells were stimulated with either ultrapure LPS or pIC-
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RNA. In A-D IL-6 production was measured in supernatants by ELISA. Results shown are 
mean ± SEM from two identical experiments.  * Indicates p < 0.05 vs. imiquimod or CpG 
stimulation, by one-way ANOVA followed by post hoc Bonferroni’s test. 
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Figure 19. IRS661 and IRS954 specifically inhibits imiquimod- and CpG-DNA-
induced TNF-α release in spleen monocytes from MRLlpr/lpr mice in vitro. Spleen 
monocytes from MRLlpr/lpr mice were incubated with imiquimod and IRS661 at different 
concentrations as indicated or standard medium without supplements for 24 hours as 
indicated. A-C: Spleen monocytes were incubated with either imiquimod or CpG-DNA 
alone or imiquimod plus CpG-DNA. D: Cells were stimulated with either ultrapure LPS 
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or pIC-RNA. In A-D TNF-α production was measured in supernatants by ELISA. Results 
shown are mean ± SEM from two identical experiments.  * indicates p < 0.05 vs. 
imiquimod or CpG stimulation, by one-way ANOVA followed by post hoc Bonferroni’s 
test. 
 
4.3.2. Inhibitory oligos block imiquimod- or CpG-ODN-induced IL-12p40 serum levels 
in MRLlpr/lpr mice  
In view of the in vitro efficacy of IRS661 and IRS954 to block imiquimod- or CpG-
DNA-induced cytokine production in spleen monocytes, it was questioned whether these 
effects do also apply to MRL-lpr/lpr mice in vivo. Five groups of 14 week old MRL-
lpr/lpr mice (n=5-8) were injected intraperitoneally with a single dose of either saline, 25 
μg imiquimod or 40 μg CpG-DNA in the presence or absence of a single dose of IRS661 
or IRS954 (40 μg) 30 min before the administration of the agonist. Serum IL-12p40 
levels were determined after 3 hours of agonist administration by ELISA. Imiquimod and 
CpG-DNA significantly induced the serum levels of IL-12p40 as compared to saline-
injected control mice (Figure 20). IRS661 and IRS954 both significantly reduced the 
imiquimod-induced induction of IL-12p40. IRS954 significantly reduced the CpG-DNA-
induced induction of IL-12p40. Thus, 40 μg of IRS661 and IRS954 was observed to 
block Tlr7 or Tlr9 mediated effect in vivo.   
 
 
 
 
  - 98 - 
                       
 
Figure 20. IRS661 and IRS954 block imiquimod- and CpG-DNA-induced IL-12p40 
production in vivo. Groups of 14 week old female MRLlpr/lpr mice (n=5) were injected 
with saline or a single dose of 25 μg imiquimod (imi) or 40 μg CpG-DNA (CpG) or 40 μg 
IRS as indicated. Serum IL-12p40 levels were determined after 3 hours by ELISA. Data 
represent means ± SEM. * p < 0.05 vs. saline, # p < 0.05 vs. imiquimod, † p < 0.05 vs. 
CpG-DNA.  
 
4.3.3. Serum cytokine levels of MRLlpr/lpr mice injected with Tlr7 and Tlr7/Tlr9 
inhibitory oligos from week 11 to 24 
It is known that Tlr7 and Tlr9 signaling activates the expression of proinflammatory 
cytokines and type I interferons (Akira et al, 2006). Hence, it was assessed whether 
injections with IRS661 or IRS954 from week 11 to 24 of age affected the serum levels of 
these mediators in MRLlpr/lpr mice by ELISA. We observed that, both IRS661 and 
IRS954 significantly reduced the serum levels of TNF as compared to saline-injected 
MRLlpr/lpr mice (Table 9). IL-6 levels were also decreased with IRS954, the trend did 
not reach statistical significance for IRS661 (Table 9). Contrarily, serum IL-12p40 levels 
were found to be only reduced with IRS661 injections but not with IRS954. Interferon-α 
levels were not affected by either IRS oligo (Table 9).  
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Table 9. Serum factors and lymphoproliferation in 24 week old MRL lpr/lpr mice. 
   
Saline 
 
IRS661 
 
IRS954 
     
Serum  IL-6  [pg/ml] 90.3 ± 31.3 58.1 ± 16.8 26.9 ± 3.1* 
             TNF  [pg/ml] 23.9 ± 4.0 4.4 ± 2.3* 5.8 ± 4.4* 
             IL-12p40  [ng/ml] 5.3 ± 1.1 3.4 ± 0.7* 4.6 ± 0.7 
             IFN-α  [pg/ml] 35.4 ± 8.3 30.6 ± 7.5 37.5 ± 7.9 
             IgG1  [mg/ml] 38.4 ± 4.7 29.4 ± 4.8 34.4 ± 4.0 
             IgG2a  [mg/ml] 12.0 ± 1.3 9.1 ± 1.7 12.9 ± 1.1 
             IgG2b  [mg/ml] 9.2 ± 2.1 6.1 ± 1.1 5.8 ± 1.4 
             IgG3  [mg/ml] 3.2 ± 0.2 3.3 ± 0.3 2.9 ± 0.2 
  Anti-dsDNA IgG1  [μg/ml] 15.0 ± 6.3    14.7 ± 6.2 34.2 ± 12.7 
                        IgG2a  [μg/ml] 38.0 ± 7.1 18.9 ± 2.7* 56.8 ± 12.9# 
                        IgG2b  [μg/ml] 46.3 ± 9.5 18.2 ± 2.3* 34.8 ± 7.2# 
                        IgG3  [μg/ml] 27.7 ± 3.7 21.8 ± 2.1 24.1 ± 2.2 
  Anti-Sm IgG  [μg/ml] 8.8 ± 3.4   4.4 ± 1.1* 10.2 ± 2.8# 
  Rheumatoid factor  OD (450 nm)   0.88 ± 0.14 0.86 ± 0.13 0.81 ± 0.13 
Lymph node weight  [mg/g BW] 16.7 ± 1.7 8.5 ± 1.6* 9.1 ± 0.6* 
Spleen weight  [mg/g BW] 8.9 ± 0.8 6.7 ± 0.5* 6.1 ± 0.4* 
            CD4+ cells  % spleen 18.1 ± 3.4 17.6 ± 4.8 19.4 ± 4.3 
            CD8+ cells  % spleen 8.7 ± 1.7 9.7 ± 2.7 9.0 ± 2.0 
            CD4-/CD8-  % spleen 62.3 ± 1.4 51.7 ± 3.4* 57.5 ± 1.5* 
 
N = 10 per group, values are means ± SEM, * p < 0.05 IRS661 or IRS954 vs. saline,  
# p < 0.05 IRS954 vs. IRS661 by unpaired t test 
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Figure 21. Serum Anti-SmRNP IgG levels in treated mice: 3 Groups of 24 weeks old 
female MRLlpr/lpr mice (n=10) were treated for 13 weeks (from week 11 to 24) with 
saline or IRS661 or IRS954. Serum anti-SmRNP IgG levels were determined by ELISA. 
Data represent mean ± SEM.   
 
4.3.4. Tlr7 inhibitory oligo reduces serum autoantibody levels in MRLlpr/lpr mice  
Tlr7 and Tlr9 were shown to have distinct effects on the production of antinuclear 
antibodies in MRLlpr/lpr mice (Christensen et al, 2006). Hence, it was assessed whether 
injections with IRS661 and IRS954 from week 11 to 24 of age affected serum IgG and 
autoantibody levels. Serum levels of IgG1, IgG2a, IgG2b and IgG3 were not significantly 
affected by either IRS (Table 9). Antinuclear antibody staining on Hep2 cells revealed 
positive nuclear signals in each MRLlpr/lpr mouse of all groups (Figure 22A). In saline-
treated MRLlpr/lpr mice a homogenous nuclear staining was most common. Positivity of 
condensed chromosomal areas of mitotic cells was indicative for autoantibodies directed 
against chromatin. A speckled nuclear staining pattern was less frequent and a 
cytoplasmic staining pattern was not observed. In IRS661-treated MRLlpr/lpr mice the 
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homogenous pattern was less frequent and speckled pattern was somewhat more frequent 
as compared to saline treated mice. Sera of IRS954 treated mice showed an equal 
distribution of homogenous and speckled nuclear staining patterns (Figure 22A). 
Antinuclear antibodies specific for dsDNA were studied by the specific binding to 
kinetoplast DNA of Crithidia luciliae. IRS661 but not IRS954 significantly reduced the 
indirect immunofluorescence intensity of mouse serum (at a dilution of 1:100) incubated 
with Crithidia luciliae substrates (Figure 22B). Assessing the binding of serum to 
polylysine-linked dsDNA by ELISA is another method to determine the specificity of 
antinuclear antibodies. IRS661, but not IRS954, significantly reduced serum levels of 
dsDNA-specific IgG2a IgG2b, and anti-Sm IgG antibodies as compared to saline-treated 
MRLlpr/lpr mice (Table 9). Anti-Sm IgG and anti-Sm RNP IgG were reduced upon 
IRS661 treatment to the same extent (Table 9, Figure 21). Anti-dsDNA IgG1, and IgG3 
levels as well as rheumatoid factors were not affected by either IRS. These findings are 
suggestive of an inhibitory effect of IRS661 on the production of anti dsDNA IgG2a and 
IgG2b antibodies, which are known to induce glomerular pathology in MRLlpr/lpr mice 
by activating complement (Lucisano et al; Ehlers et al, 2006). Interestingly, glomerular 
deposits of IgG2a and complement factor C3c were significantly reduced in both IRS661- 
and IRS954-injected MRLlpr/lpr mice (Figure 23, Table 10). Together these data 
indicate that injections with IRS661 but not with IRS954 reduce the production of 
selected autoantibodies. Glomerular complement activation was reduced with either IRS, 
independent of circulating IgG2a isotype levels, suggesting that IRS can modulate 
immune complex deposition and complement activation independent of circulating 
autoantibody levels in MRLlpr/lpr mice. 
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Figure 22. IRS661 and IRS954: Antinuclear antibodies and glomerular immune 
complex deposits in MRLlpr/lpr mice. A: Serum antinuclear antibodies were detected by 
Hep2 slide staining as described in methods. Staining patterns were classified as 
homogenous, speckled or cytoplasmic. Positive staining of mitotic chromatin was 
assessed independently of the other staining patterns. Data shown on the right represent 
the staining pattern present in percent of mice of each group as indicated. B: Serum 
antibodies against Crithidia luciliae kinetoplast DNA were analysed as described in 
methods. Data represent staining intensity of sera from individual MRLlpr/lpr mice from 
each group. * p < 0.01 vs saline by two-tailed Mann Whitney U test. 
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Figure 23. Glomerular immune complex and C3c deposits in MRLlpr/lpr mice. 
Paraffin-embedded renal sections were stained for IgG1 and IgG2a as indicated (original 
magnification 400x). In saline-treated mice IgG1 and IgG2a localize to the mesangium 
and the glomerular capillary wall. Note that IRS661- and IRS954-treated MRLlpr/lpr 
mice show less IgG2a deposits. Frozen renal sections were stained for complement factor 
C3c. Note the robust glomerular complement activation in saline-treated MRLlpr/lpr mice 
which was much lower detectable in IRS661- and IRS954-treated MRLlpr/lpr mice. 
Images are representative for 10 mice in each group (original magnification 400x). 
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4.3.5. Tlr7 and Tlr9 inhibition reduce lymphoproliferation and protect MRLlpr/lpr 
mice against autoimmune tissue injury 
Based on the reported phenotype of Tlr7-deficient MRLlpr/lpr mice (Christensen et al, 
2006) and our own data with IRS661, a course of injections with IRS661 from week 11 
to 24 of age might have beneficial effects on experimental lupus of MRLlpr/lpr mice. 
Compared to the phenotype of Tlr9-deficient MRLlpr/lpr mice (Christensen et al, 2006) 
the effects of IRS954 on experimental lupus were found to be quite opposite in this study. 
IRS661 and IRS954 significantly reduced the weight of spleens and mesenteric lymph 
nodes in MRLlpr/lpr mice as compared to saline-treated controls (Table 9). IRS661 and 
IRS954, also reduced the numbers of CD4/CD8 double negative CD3+ T cells in spleen 
while the numbers of spleen CD4+ cells and CD8+ cells remained unaffected (Table 9). 
These data indicate that both IRS reduce lymphoproliferation and the expansion of 
CD4/CD8 double negative ‘autoreactive’ T cells in MRLlpr/lpr mice. Both, IRS661 and 
IRS954, also significantly reduced the numbers of glomerular and interstitial Mac-2 
macrophages and of interstitial CD3 lymphocytes (Table 10, Figure 25). Proteinuria is a 
clinically important marker of lupus nephritis but usually it shows a high interindividual 
variability in female MRLlpr/lpr mice. Thus, the trend to decreased proteinuria in 
IRS661- and IRS954-treated MRLlpr/lpr mice did not reach statistical significance. 
Furthermore, we evaluated extrarenal autoimmune tissue injury in lungs of MRLlpr/lpr 
mice. Lungs of IRS-treated MRLlpr/lpr mice showed less peribronchiolar and 
perivascular inflammatory cell infiltrates compared with saline-treated controls (Table 
10, Figure 25). Together these data shows that IRS661 and IRS954 both reduce 
autoimmune tissue injury in lungs and kidneys of MRLlpr/lpr mice. 
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Figure 25. Lupus nephritis and lung injury in MRLlpr/lpr mice. A. Renal sections were 
stained with PAS, Mac-2, and CD3 as indicated (original magnification 200x). Note that 
IRS661- and IRS954-treated MRLlpr/lpr mice show less periglomerular, and interstitial 
inflammatory cell infiltrates as compared to saline-treated MRLlpr/lpr mice. B: Lungs 
sections taken from 24 weeks old MRLlpr/lpr mice of all groups were stained with PAS. 
Note that IRS661- and IRS954-treated MRLlpr/lpr mice show less peribronchiolar and 
perivascular inflammatory cell infiltrates as compared to saline-injected MRLlpr/lpr 
mice. Images are representative for 10 mice in each group (original magnification 200x).  
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Table 10. Urinary finding in 24 weeks old MLR lpr/lpr mice. 
  
 
 
Saline 
 
IRS661 
 
IRS954 
  U. albumin/ creat.  [mg/mg] 4.3 ± 1.6 1.7 ± 0.8 2.6 ± 0.7 
 
N = 10 per group, values are mean ± SEM, Glom. = glomerular, Int. = interstitial,  
* p < 0.05 IRS661 or 954 vs. saline, by unpaired t test 
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5. Discussion 
 
5.1. Ligation of TLR7 did not lead to induction of lupus nephritis 
In vitro studies suggest that the microbial nucleic acids can modulate autoimmunity 
through multiple mechanisms but their impact on the onset of lupus nephritis in MRLlpr/lpr 
mice at young age was not known (Lau et al, 2005; Leadbetter et al, 2002; Means et al, 
2005, Pasare et al, 2003; Pasare et al, 2005, Rifkin et al, 2005, Krieg et al, 1995, Krieg et 
al, 2005). In this study young MRLlpr/lpr and MRL wild-type mice were used to study 
the effects of an intermittent exposure to Tlr7 ligand, imiquimod, on lymphoproliferation 
and autoantibody production in genetically predisposed and non-predisposed hosts. It was 
found that Imiquimod did not cause DNA autoantibody production or glomerulonephritis 
in MRL wild-type or MRLlpr/lpr mice. These data confirms that although Tlr7 is an 
important receptor for the pathogenesis of lupus but an exposure to the Tlr7 ligand at the 
given dose in young healthy age do not lead to induction of lupus in genetically 
predisposed and non-predisposed mice. 
 
5.2. Ligation of TLR7 leads to significant aggravation of established lupus  
Viral infections can aggravate disease activity in preexisting SLE, but the role of TLR7 
ligation by viral ssRNA or it’s synthetic mimic was not yet proven mechanistically in a 
mouse model of lupus nephritis. Hence in this project MRLlpr/lpr mice were used to 
study the effects of intermittent exposure to imiquimod, a synthetic Tlr7 ligand with 
immunostimulatory effects comparable to viral ssRNA (Heil et la, 2004; Hemmi et al, 
2002).  In this study we found evidence for an intracellular expression of Tlr7 on renal 
macrophages and dendritic cells in nephritic lesions of MRLlpr/lpr mice. Spleen 
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monocytes and bone marrow-derived dendritic cells produce proinflammatory cytokines, 
chemokines, and type I interferons upon ligation of Tlr7. The immunostimulatory effects 
of ssRNA relates to the cell type-specific expression pattern of Tlr7. These data may 
provide a new understanding of viral infection-induced exacerbation of lupus nephritis as 
well as other types of glomerulonephritis. 
Antiviral host defense requires activation of innate immunity including the local 
production of type I interferons and chemokines. The finding that injected ssRNA 
localized to Tlr7 positive macrophages in kidneys of MRLlpr/lpr mice suggests a role for 
Tlr7 in activating renal macrophages in the kidney. Our studies with spleen monocytes 
isolated from MRLlpr/lpr mice favours Tlr7 activation and its effect on tissue 
macrophages contributing to the local production of proinflammatory mediators 
including Il-12, Il-6, Ccl2, Ifn-α which are known to contribute to the progression of 
lupus nephritis.  As Tlr7 positive macrophages were mainly detected in the renal 
interstitium, we suggest that the aggravation of glomerular injury in imiquimod-treated 
MRLlpr/lpr mice could be secondary to increased glomerular immune complex 
deposition. Furthermore, a low number of CD11c positive dendritic cells were found to 
express Tlr7 in the kidney. The functional role of intrarenal CD11c positive dendritic 
cells for the progression of nephritis in MRLlpr/lpr mice was unclear. Our in vitro data 
with CD11c positive bone marrow-derived dendritic cells suggest that this cell type 
contributes to local production of proinflammatory mediators, i.e. Il-6, Il-12, Ccl2, and 
Ifn-α. For example, Il-6 produced by either renal macrophages or CD11c positive 
dendritic cells may suppress regulatory T cells that control autoreactive T cells and 
proliferation of T cells in total (Pasare et al, 2003). In the present study exposure to 
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imiquimod increased serum levels of the aforementioned mediators and aggravated 
autoimmune tissue injury in kidneys and lungs of the MRLlpr/lpr mice. This was 
associated with enhanced renal production of the chemokine Ccl2 and increased 
interstitial macrophage and T cell infiltrates. Based on similar effects of Tlr7, -3, and -9 
ligands on cytokine and chemokine production by monocytes and dendritic cells, these 
data add to the concept of how nucleic-acid-specific Tlrs on antigen-presenting cells can 
modulate autoimmunity, e.g. lupus nephritis (Rifkin et al, 2005; Krieg et al, 2002).  
Immunostaining for Tlr7 revealed that intrinsic renal cells do not express Tlr7. In 
addition, labelled ssRNA did not localize to intrinsic renal cells after injection. These 
observations were consistent with our findings in cultured mesangial cells, that did not 
express Tlr7 mRNA and did not respond to imiquimod. So far Tlr7 has not been reported 
to be expressed in any non-immune cell type (Nishimura et al, 2005). Thus, the 
expression of Tlr7 appears to be restricted to antigen-presenting cells in mice and humans 
(Hornung et al, 2002). These data indicate that imiquimod-induced aggravation of 
nephritis in MRLlpr/lpr mice is unrelated to direct activation of intrinsic renal cells.  
Lupus is characterized by polyclonal autoantibody production and B cell proliferation, 
the latter expressing Tlr7 at intermediate levels (Hornung et al, 2002). Tlr7 ligation with 
repeated injections of imiquimod in MRLlpr/lpr mice, was associated with a trend 
towards increased serum dsDNA autoantibody levels, a significant increase in glomerular 
immune complex deposits and complement activation. The latter may explain, why 
imiquimod aggravated glomerular injury in MRLlpr/lpr mice despite having no effect on 
glomerular macrophage counts. The finding that imiquimod had only a moderate effect 
on autoantibody production is supported by a recent study, showing that B cells do not 
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respond to Tlr7 ligands unless their B cell sensitivity is enhanced due to IFN-α released 
by dendritic cells (Berkeredjian-Ding et al, 2005). Tlr7 ligands alone cannot induce B 
cell activation because interferon-producing dendritic cells control Tlr7 sensitivity of B 
cells. We assume that imiquimod had a moderate effect on B cell-dependent production 
of dsDNA autoantibodies in MRLlpr/lpr mice because B cells localize in close proximity 
to interferon-producing dendritic cells in lymphoid organs and imiquimod injection 
increased serum IFN-α levels in MRLlpr/lpr mice. It was found that, imiquimod and 
ssRNA induce IFN-α production in bone marrow-derived dendritic cells isolated from 
MRLlpr/lpr mice. Unlike CpG-Tlr9-mediated activation of B cells, Tlr7 ligation requires 
additional cofactors, e.g. IFN-α, in order to mount B cell activation and subsequent DNA 
autoantibody production. Thus, Tlr7 ligation has a moderate effect on autoantibody 
production in MRLlpr/lpr mice. 
In this study it was found that the Tlr7 could activate B cells only in the presence of 
additional cofactors, which result in an intermediate increase of autoantibody production 
and glomerular immune complex deposition. In addition, Tlr7 induce dendritic cell 
maturation towards an antigen-presenting phenotype as well as production of 
proinflammatory cytokines, chemokines, and type I interferons by renal macrophages. 
These results also suggest that endogenous TLR7 ligand plays a role of adjuvant rather 
than a causative factor for aggravation of autoimmunity. However the role of TLR7 or 
endogenous TLR7 ligands such as smRNP, in breaking the tolerance checkpoints which 
leads to relentless growth of self reactive B and T lymphocytes (Goodnow, 2007) is not 
yet known. It is suggested that multiple genetic mutations might be needed before self-
reactive clone bypasses sequential tolerance checkpoints resulting in emergence of 
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autoimmune disease (Goodnow, 2007). Hence it might be possible that TLR7 plays a role 
of amplification factor in lupus. 
In summary, these results contribute to the understanding of the broad clinical spectrum 
and universal serum markers of infection-associated disease activity of lupus nephritis 
and possibly other types of immune complex glomerulonephritis. 
  
5.3. Blockade of TLR7 or double blockade of TLR7 and TLR9 in lupus nephritis is 
protective 
Nuclear lupus autoantigens trigger autoantibody production and the release of 
proinflammatory mediators by activating Tlr7 and Tlr9 in B cells and dendritic cells in 
vitro (Leadbetter et al, 2002, Lau et al, 2005; Means et al, 2005; Barrat et al, 2005; 
Lovgren et al, 2004; Savarese et al, 2006; Vollmer et al, 2005). Blocking Tlr9 signaling 
with injections of specific oligodeoxynucleotides could ameliorate lupus nephritis in 
MRLlpr/lpr mice (Patole et al, 2005; Dong et al, 2005), hence we hypothesized that 
antagonism of Tlr7 or Tlr7 plus Tlr9 may be effective in vivo.  
Injections with TLR7 antagonist IRS661 were started from week 11 of age till 24 weeks. 
This could substantially reduced autoimmune tissue lung and kidney injury at week 24 of 
age which is also consistent with the phenotype of Tlr7-deficient MRLlpr/lpr mice 
(Christensen et al, 2006). These data support a role of Tlr7 for the mechanisms that foster 
the progression of autoimmune tissue injury in MRLlpr/lpr mice, e.g. the expansion of 
the autoreactive CD4/CD8 double negative autoreactive T cell population, immune 
complex-mediated local complement activation, and the local inflammatory response 
involving macrophage and T cell recruitment (Kotzin et al, 1996; Lipsky et al, 2001; 
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Singh et al, 2006). TLR7 antagonist, IRS661 significantly reduced the number of 
CD4/CD8 double negative T cells in spleen, a population which continuously expands in 
MRLlpr/lpr, because of the inability to delete autoreactive and activated T cells in mice 
via the interaction of Fas with the Fas-ligand in these mice (Cohen et al, 1991). 
Autoantibody production is another characteristic feature of MRLlpr/lpr mice and 
contributes to autoimmune tissue injury via immune complex formation and local 
complement activation. Interestingly, Tlr7 is particularly required to generate anti-Sm 
RNP IgG (Christensen et al, 2006) and serum levels of anti-Sm RNP IgG were also 
reduced with injection of IRS661. Furthermore, we found that IRS661 reduced the serum 
levels of anti-dsDNA IgG2a and IgG2b. We also observed that, the glomerular deposits of 
IgG2a and complement factor C3c were both reduced in IRS661-treated mice, indicating a 
role for Tlr7 in the production of selected nephritogenic autoantibodies and immune 
complex-glomerulonephritis in MRLlpr/lpr mice. In this study we used identical assay 
systems as reported by Christensen et al, and we found that the data from both the labs 
consistently show that blockade or lack of Tlr7 does not substantially reduce homogenous 
nuclear and mitotic ANA staining of Hep2 cells (Christensen et al, 2006). In reports from 
same lab (Christensen et al, 2005 and 2006), 20-30 % of lpr mice showed speckled 
nuclear pattern indicating the presence of anti-SmRNP, autoantibodies which was 
confirmed by western blots for Sm binding activity, which supports our results that 
inhibition of Tlr7 lupus mice leads to decrease in levels of anti sm-RNP or anti-Sm 
antibodies. Our data is consistent and supported by results from other groups recently 
(Christensen et al, 2006) which showed that Tlr7 deficient lpr mice produced anti-
DNA/anti-chromatin autoantibodies but not anti Sm-RNP antibodies. The Tlr7 deficient 
  - 114 - 
lpr mice also have lower IgG2a and IgG titres than their Tlr-sufficient wild-type 
littermates as well as reduced numbers of activated T cells and PDCs (nevertheless, renal 
disease was decreased only moderately) (Christensen et al, 2006). Another study also 
showed similar results with lpr mice deficient in MyD88 failed to produce both DNA and 
Sm-reactive antibodies (Lau et al, 2005). Tlr7 also appears to play a role in activation of 
B cells that express transgene encoded 564 Igi B cells spontaneously produce antibodies 
that give cytoplasmic Hep-2 staining pattern and form ICs that deposit in kidney. Tlr7 
deficient 564Igi B cells no longer spontaneously produce 564 Igi antibodies (Berland et 
al, 2006). 
Together, the beneficial effects of Tlr7 blockade with IRS661 on autoimmune tissue 
injury of MRLlpr/lpr mice were associated with a reduction of CD4/CD8 double negative 
T cells, reduction in levels of pathogenic autoantibodies, and reduction in levels of 
proinflammatory chemokines in kidney, known to mediate immune cell recruitment into 
the tissue.  
When we were performing these studies in our lab, some new results were published 
about Yaa mice, as reported by Subramanian et al (2006) and Pisitkun et al (2006), 
transgenic models with autoimmune accelerator on Y chromosome. The Yaa loci 
consisting of Tlr7 and 16 other genes from X chromosome which were duplicated on Y 
chromosome in these mice. Another study had reported Tlr7 transgene founder lines in 
transgenic BL6 mice, which were showed to have Tlr7-gene dosage dependent disease 
severity of lupus in such mice and Tlr7 gene dependent increase in RNA antibodies and 
increased nucleolar and speckled nucleolar patterns by such mice sera in Hep-2 slides 
(Deane et al, 2007). It also had severe effects on survival of these mice dependent on Tlr7 
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gene dosage compared to WT-BL6 mice. Altogether the results suggest that Tlr7 is 
responsible in progression and development of lupus. 
Given the opposing effects of Tlr7 and Tlr9 deficiency in MRLlpr/lpr mice (Christensen 
et al, 2006; Wu et al, 2006) the effects of Tlr7/Tlr9 dual antagonist IRS954 were quite 
different. Injections with IRS954 from week 11 to 24 of age improved kidney and lung 
disease in MRLlpr/lpr mice and no additive effects were observed as compared to 
IRS661. The effects of IRS954 on lupus nephritis and lung injury are comparable to what 
has been observed with oligonucleotide antagonists specific for Tlr9 only in the same 
lupus model (Patole et al, 2005) or in NZB/NZW mice (Dong et al, 2005). These findings 
support the concept that recognition of endogenous DNA and RNA molecules via Tlr7 
and Tlr9 contribute to the progression of autoimmune tissue injury. This concept was 
developed from studies showing that lupus autoantigens in immune complexes with IgG 
prepared from autoimmune mice or lupus patients can activate B cells and dendritic cells 
in vitro (Leadbetter et al, 2002; Lau et al, 2005; Means et al, 2005; Savarese, 2006; 
Vollmer et al, 2005). These in vitro experiments and in vivo studies with Tlr9 antagonists 
are inconsistent with the aggravated phenotype of Tlr9-deficient MRLlpr/lpr mice, and 
have questioned the specificity of the antagonists and the assay systems used for the 
analysis of serum autoantibodies (Christensen et al, 2006; Lartigue et al, 2006; Wu et al, 
2006, Yu et al, 2006; Marshak Rothstein et al, 2006). Similar to our results, other groups 
have found out that Tlr9 deficient FcRIIB deficient 56R mice have decreased IgG2a and 
IgG2b titers (Ehlers et al, 2006).  
The data reported by Barrat, et al, and our own study have demonstrated the specificity of 
IRS954 for Tlr7 and Tlr9 (Barrat et al, 2005). Furthermore, by applying identical assay 
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systems as in the study reported by Christensen et al, we show that IRS954 has distinct 
effects on serum autoantibody levels as compared to IRS661 (Christensen et al, 2006). 
For example, in contrast to IRS661, IRS954 did not affect serum dsDNA autoantibodies, 
and may be Tlr9 antagonism provided by IRS954 ‘neutralized’ the suppressive effect of 
on Tlr7-mediated anti-dsDNA IgG2a, IgG2b, anti-Sm and anti-Sm-RNP IgG production. 
Furthermore, IRS954 injections were associated with fewer mice with homogenous 
nuclear staining on Hep2 cells which was consistent with what has been observed in Tlr9-
deficient MRLlpr/lpr mice (Christensen et al, 2006). The finding that IRS954 did not 
reduce dsDNA autoantibodies is potentially interesting because we previously found that 
another oligo ODN2114, blocking Tlr9 only, reduced these antibodies in MRLlpr/lpr mice 
(Patole et al, 2005). These reports suggests that the roles of Tlr7 and Tlr9 for the 
evolution of specific autoantibodies may even be more complex and requires a detailed 
analysis of immune cell subsets from Tlr7 and Tlr9 double-knock out cells which are not 
yet available. Our results were also supported by the results from another group about 
TLR7 and TLR9 dual inhibition and amelioration of disease symptoms in lupus mice 
(Barrat et al, 2007). Recent studies published about 5 separate patient cohorts have 
identified atleast two SNPs associated with IRF as high risk factor for SLE (Sigurdsson et 
al, 2005 and 2007; Graham et al, 2007), and since activation of Tlr7 and Tlr9 mediates 
the Type 1 IFN production via IRF5 and IRF7, role of these 2 receptors in pathogenesis 
of lupus has become the major contributing factor. 
In summary these data suggest that delayed onset of oligonucleotide-based inhibition of 
Tlr7 reduces autoantibody production and prevents autoimmune tissue injury in 
experimental lupus. Combined blockade of Tlr7 and Tlr9 has no additive effects. This 
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data support the concept that endogenous ligands of Tlr7 contribute to the pathogenesis 
of autoantibody production and autoimmune tissue injury in SLE and propose Tlr7 
blockade as a novel therapeutic target for lupus. 
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6. ZUSAMMENFASSUNG 
 
Die vorliegende Studie trägt zum besseren Verständnis des breiten klinischen Spektrums 
und des Fehlens universeller Serum- Marker der infektionsassoziierten 
Krankheitsaktivität der Lupus- Nephritis und möglicherweise anderer Formen der 
Immunkomplexnephritis bei. 
Exogener Kontakt mit TLR 7- Liganden hat die Entwicklung der Lupus- Nephritis bei 
jungen, gesunden MRL- Wildtyp und MRLlpr/lpr Mäusen nicht getriggert und hatte 
keinen signifikanten Effekt auf die Krankheitsaktivität bei diesen jungen Mäusen. 
Bei alten Lupus- Mäusen führte eine ähnliche Exposition jedoch zu einem merklichen 
Anstieg der Serumspiegel proinflammatorischer Zytokine und von IFNα, sowie zu einer 
Infiltration der Nierenglomeruli 18 Wochen alter MRLlpr/lpr Mäuse mit Makrophagen 
und einer (nicht signifikanten) Erhöhung der Autoantikörperspiegel. Diese Daten 
unterstützen die Theorie, dass dem Toll- like Rezeptor 7 eine Rolle bei den 
Mechanismen, die das Fortschreiten der autoimmunen Gewebsschädigung in MRLlpr/lpr 
Mäusen fördern, zukommt.  
Basierend auf den Ergebnissen der funktionellen Rolle von TLR 7 in Lupus- Mäusen und 
in Primärzellen, die aus Lupusmäusen isoliert wurden, sahen wir in der TLR 7- Blockade 
ein mögliches neues Ziel, um die schädlichen Effekte des Signalings über 
Immunkomplexe und endogene Liganden zu begrenzen. 
Es zeigte sich, dass die Blockade von TLR 7 und TLR 7 + TLR 9 die Gewebsschäden in 
Nieren und Lunge signifikant reduzieren konnte. Eine TLR 7 Antagonisierung mit dem 
Oligodeoxyribonukleotid IRS661 senkte die Menge an Autoantikörpern (insbesondere 
anti- SM, anti- dsDNA, IgG2a, IgG2b), entzündlichen Zytokine und Chemokinen im 
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Serum, glomerulären Ablagerungen von  IgG2a und Komplementfaktor C3c deutlich. Die 
Hemmung von TLR 7 reduzierte ebenfalls die CC- Chemokin- gesteuerten 
Makrophagen- und T- Zell- Infiltrate in den Nieren. Dies zeigte sich durch erniedrigte 
Spiegel von Ccr2, Ccr5, Ccl2 und Ccl5 in den Nieren behandelter Tiere. 
Diese Ergebnisse unterstützen das Konzept, dass endogene TLR 7- Liganden zur 
Pathogenese der Autoantikörperproduktion und der autoimmun vermittelten 
Gewebsschädigung des SLE beitragen. Die TLR 7- Blockade könnte ein neues 
therapeutisches Konzept beim Lupus erythematodes sein. 
 
6. Conclusion 
In summary, exogenous administration of Tlr7 ligand in young, healthy MRL-wild type 
and MRLlpr/lpr mice did not trigger the development of lupus nephritis, and did not have 
any significant effect on disease activity. Upon similar exposure in well established lupus 
produced marked increase in serum levels of proinflammatory cytokines and IFN, 
infiltration of macrophages in glomeruli of kidneys of 18 weeks old MRLlpr/lpr mice 
and trend towards increased autoantibodies level. These data support a role of Tlr7 for the 
mechanisms that foster the progression of autoimmune tissue injury in MRLlpr/lpr mice. 
Hence these studies might suggest that TLR7 is an adjuvant amplification factor rather 
than a causative factor for autoimmunity.  
Based on the results of functional role of Tlr7 in lupus mice and the primary cells isolated 
from the lupus mice suggested a new potential target of blocking Tlr7 to restrict the 
harmful effects of its downstream signalling via the immune-complexes and endogenous 
ligands. The blockade of Tlr7 and dual blockade of Tlr7 & Tlr9 resulted in efficient and 
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significant reduction of tissue injury in kidneys and lungs of lupus mice. Tlr7 antagonism 
with the oligodeoxyribonucleotide IRS661, significantly reduced the levels of 
autoantibodies (specifically anti-Sm, anti-dsDNA IgG2a, IgG2b), inflammatory 
cytokines, chemokines in serum, the glomerular deposits of IgG2a and complement 
factor C3c. Inhibition of Tlr7 also reduced CC-chemokine-driven macrophage and T cell 
infiltrates in kidneys as replicated by decreased levels of Ccr2 and Ccr5 and Ccl2 and 
Ccl5 in treated kidneys. These results support the concept that endogenous ligands of 
Tlr7 such as smRNP and RNA associated immune-complexes contribute to the 
pathogenesis of autoantibody production and autoimmune tissue injury in SLE and 
propose TLR7 blockade as a novel therapeutic target for lupus. Although the role of 
TLR7 in escape of B and T cells from the tolerance checkpoints to become self-reactive 
and loss of anergy needs to be studied in future. 
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